Elucidating the role of DNA damage and human cytomegalovirus in medulloblastoma and glioblastoma by Bartek, Jiri
From the Department of Medicine, Solna
Karolinska Institutet, Stockholm, Sweden
ELUCIDATING THE ROLE OF 
DNA DAMAGE AND  HUMAN 
 CYTOMEGALOVIRUS IN 
 MEDULLOBLASTOMA AND 
 GLIOBLASTOMA
Jiri Bartek
Stockholm 2020
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Arkitektkopia AB, 2020 
© Jiri Bartek, 2020 
ISBN 978-91-7831-722-6
Elucidating the role of DNA damage 
and Human Cytomegalovirus in 
Medulloblastoma and Glioblastoma
THESIS FOR DOCTORAL DEGREE (Ph.D.)
The thesis will be defended at Karolinska Universitetssjukhuset, Norrbacka 
S2:01 (Rehabsalen), Eugeniavägen 39, Solna
Thursday, April 2, 2020 at 8.30
By
Jiri Bartek
Principal Supervisor:
Cecilia Söderberg-Naucler, Professor 
Karolinska Institutet 
Department of Medicine, Solna 
Division of Microbial Pathogenesis
Co-supervisors:
Afsar Rahbar, PhD 
Karolinska Institutet 
Department of Medicine, Solna 
Division of Microbial Pathogenesis
Giuseppe Stragliotto, MD, PhD 
Karolinska Institutet 
Department of Medicine, Solna 
Division of Microbial Pathogenesis
Mikael Svensson, Professor 
Karolinska Institutet 
Department of Clinical Neuroscience 
Division of Neurosurgery
Opponent:
Einar Vik-Mo, PhD 
Oslo University 
Department of Clinical Medicine 
Division of Neuroscience
Examination Board:
Susan Pfeifer, Professor 
Uppsala University 
Department of Women and Child Health 
Division of Molecular Genetics
Leif Salford, Professor 
Lund University 
Department of Clinical Sciences 
Division of Neurosurgery
Oscar Fernandez-Capetillo, Professor 
Karolinska Institutet 
Department of Medical Biochemistry  
and Biophysics 
Division of Genome Biology

To my family

ABSTRACT
The most common primary malignant brain tumor in children is Medulloblastoma, 
while Glioblastoma is the most common in adults. Treatment for both include some 
combination of surgery, radiation therapy, and chemotherapy. The evolution of most 
primary malignant brain tumors is unknown, although varying degree of genomic 
instability caused by defects in the DNA Damage Response (DDR) is suspected. 
Lately, even human cytomegalovirus (HCMV) has emerged as a suspected patho-
gen possibly implicated in malignant tumor evolution. Nevertheless, the causes of 
the chromosomal instability and its potential links with HCMV infection and/or 
resistance to genotoxic therapies (i.e. radiation and chemotherapy) remain largely 
unknown. Thus, the main aim of this PhD thesis is to investigate the role of HCMV 
in the context of DDR in human Medulloblastoma and Glioblastoma.
In the 1st study, we turned our attention towards Glioblastoma (GBM). We examined 
the ability of HCMV to induce a more aggressive cancer stem cell (CSC)-like pheno-
type in primary GBM cell lines. HCMV infection induced a stem cell phenotype in 
primary GBM cell lines as determined by changes in the cellular gene expression 
profile and by the conferred ability of cells to grow as neurospheres in vitro, and this 
phenotype was prevented by treatment with the anti-viral drug ganciclovir. As CSCs 
are known to be resistant to chemotherapy, our results imply that HCMV may enhance 
the malignancy grade of the tumor, and possibly contribute to therapy resistance.
In the 2nd study, we found pronounced endogenous DNA damage signaling and con-
stitutive activation of DNA damage checkpoint kinase cascades across our medullo-
blastoma cohort. The bulk of the specimens also showed expression of HCMV 
immediate early and late proteins, in comparative analyses using three immuno-
histochemical protocols. Cell culture experiments validated the chronic endogenous 
replication stress in medulloblastoma cell lines and showed sharply differential, 
intriguing responses of normal cells and medulloblastoma cells to HCMV infection. 
Our results strongly indicate that in human medulloblastomas, the DDR checkpoint 
barrier is widely activated, at least in part due to replication stress. Furthermore, 
we propose that unorthodox the highly prevalent HCMV may impact the medullo-
blastoma host cell replication stress and DNA repair mechanisms. 
In the 3rd study, we examined cancer stem cell markers (CD133, CD15, VEGFR2) 
and HCMV protein expression in human medulloblastoma specimens and medullo-
blastoma cell lines, at the same time considering also the replication stress and DNA 
damage response, as cancer stem cells are often more resistant to standard-of-care 
radiation and chemotherapy treatments. Our immunohistochemistry analysis on clini-
cal material identified widespread expression of the VEGFR2 receptor and CD15, 
yet more limited expression of CD133 compared to GBM. In addition, assessments 
of expression of HCMV early and late proteins have been carried out in parallel, 
along with cell culture experiments with HCMV infection and replication stress 
responses in medulloblastoma cell lines. Remarkably, we found that unlike the 
‘non-stem cell’ medulloblastoma cell lines, the cell line that showed robust stemness 
phenotype featured a very distinct response to DNA replication stress and HCMV 
infection, both emerging hallmarks of brain cancers.
In the 4th study, we show that HCMV infection induced replication stress (RS) and 
triggered host DNA damage response (DDR) in permissive and non-permissive 
human cells. Further, we show that undergoing standard-of-care genotoxic radio-
chemotherapy in patients with HCMV-positive glioblastomas correlated with 
elevated HCMV markers after tumor recurrence. We propose a model to explain 
oncomodulatory effects of HCMV, through RS induction, DDR subversion, cell 
death inhibition and host-cell’s genome destabilization. Our findings provide fresh 
insights into HCMV pathobiology and inspiration for future strategies to combine 
radio-chemotherapy with anti-viral drugs for cancer treatment.
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11 INTRODUCTION
1.1 Glioblastoma (GBM)
GBM is the most common primary malignant brain tumor in adults. Despite inten-
sive research for several decades, GBM biology is still not fully understood, with 
the disease characterized by aggressive tumor growth, poor response to therapy 
and overall dismal prognosis. 
1.1.1 Epidemiology
Being the most common malignant primary brain tumor, GBM accounts for 54% 
of all gliomas and 16% of all primary brain tumors 1. The incidence of GBM is 
approx. 3 per 100.000 persons in the Western countries, with an increased frequency 
in males compared to females (1.6:1), and in Caucasians compared to Africans and 
Afro-Americans (2:1), and with lowest incidence in Asians and American Indians. 
The median age at diagnosis is 64 years, implying high absolute number of cases 
among elderly (peaking at 75-84 years), which, without an effective treatment, 
will keep increasing with growing and aging populations. The age at diagnosis 
tends to be higher for primary GBM (mean age of 55 and median age of 64) than 
for secondary GBM (mean age of 40 years) 1,2. GBM is uncommon in children, 
representing only 3% of all central nervous system (CNS) and brain tumors among 
patients aged 0-19 years 2. 
The supratentorial region is the preferred location for GBM – the highest incidence 
being in the frontal lobe, followed by the temporal and parietal lobes, and finally 
the occipital lobe 3. GBM is rarely seen in the cerebellum and the spinal cord 3. Risk 
factors for GBM include prior radiotherapy, immune factors and immune genes, 
decreased susceptibility to allergy and some single nucleotide polymorphisms 
detected by genomics 4-6. Also, there is increased incidence of GBM in patients 
with hereditary tumor syndromes such as Turcot- 7 and Li-Fraumeni syndrome 
8. Inconsistent and inconclusive results have been recently published regarding 
the link between mobile phone usage and risk of glioma 9,10. Besides the above-
mentioned factors, GBM occurs sporadically without other known predispositions 
11. On the other side, protective factors include the use of anti-inflammatory drugs 
(i.e. NSAID) 12 and even genotypes that increase the risk of asthma and/or having 
allergies or atopic disease (i.e. eczema, asthma, psoriasis) 6,13.
The prognosis for GBM patients is poor, mainly decided by the level of treatment, 
but even by predictive clinical before treatment initiation such as age, comorbidity 
and functional performance status 14,15. If left untreated, the median patient survival 
is 3 months, while maximal safe surgical resection, followed by radiation- and 
chemotherapy (the so called Stupp regimen) results in up to 15 months median 
2overall survival 16,17, with 2-year survival rates at 27%, while still less than 5% of 
patients survive 5 years following diagnosis 18. Overall, survival rates for patients 
with GBM have shown no notable improvement in population statistics in the last 
three decades.
1.1.2 Pathogenesis and Classification 
Pathogenesis
In cancer, the cell of origin refers to the normal cell that acquires the initial cancer 
promoting genetic hit or hits, which then leads to cancer- and/or tumorigenesis 19. 
The cellular origin of gliomas remains a topic of controversy in cancer research. 
Nevertheless, recent advances in science have brought us new insights into the 
subject. Neural stem cells (NSC) give rise to progenitor cells that display a vary-
ing degree of potentiality, all of whom have experimentally been shown to induce 
various GBM subtype formation, depending on which driver line and driver muta-
tions have been used 20-23. As such, currently it is believed that different progenitor 
cells can function as the cell of origin. On the other hand, the role of post-mitotic, 
fully differentiated cells in the GBM formation is controversial, with astrocytes 
not easily forming glioma when targeted in experiments 21,22, while reports exist on 
differentiated neurons transforming into tumors 24, possibly caused by dedifferen-
tiation of normal cells (i.e. astrocytes and neurons), reprogrammed into stem cells 
and then transforming into GBM 24. Whether specific cells of origin are susceptible 
to certain mutations is not agreed upon, but data from experimental animal mod-
els suggest wide susceptibility to mutations in both stem- and progenitor cells 19. 
Specific cell types may exhibit preferential vulnerability to certain mutations, and 
some of these combinations might lead to specific GBM types/subtypes 21. Overall, 
these mechanisms and suggested interactions might also explain the genetic het-
erogeneity of GBM. 
Classification
GBM is classified as grade 4 astrocytoma according to the World Health Organization 
(WHO) grading system of central nervous system malignancies 25,26. The WHO 
grading system has so far been a histopathological grading system, taking into con-
sideration numerous histopathological features, of which it is mainly necrosis and 
microvascular proliferation, in combination with rapid- (high mitotic index) and 
infiltrative growth that characterizes GBM and separates GBM from Low Grade 
Glioma (LGG) 26. Recently (2016), the WHO grading system has been revised to 
incorporate molecular parameters and make use of layered diagnostic reports as 
stated in the ISN-Haarlem guidelines 27. The ISN-Haarlem guidelines consist of a 
four-layered reporting system including the histological diagnosis, the histologi-
cal grade and molecular information that when interpreted results in an integrated 
diagnosis. As such, the new classification subdivides GBM into IDH-wildtype 
(including Giant cell GBM, Gliosarcoma and Epitheloid glioblastoma), IDH-mutant 
3and NOS (Not Otherwise Specified) 26. If no consensus can be reached between 
the histopathological and the molecular diagnosis, the molecular diagnosis will 
overrule the histopathological diagnosis and dictate the diagnosis. Also, since 
combined histopathological and molecular information might not be available for 
all tumors, the 2016 classification utilizes the NOS (Not otherwise specified) to 
name those diagnostic categories that are not precisely defined (Figure 1). 
Figure 1. 2016 WHO classification of adult diffuse glioma, from 28.
Isocitrate Dehydrogenase (IDH) plays a central role in the 2016 WHO classifi-
cation. The IDH gene exists in 5 variants, encoding 3 enzymes, all of which are 
involved in the oxidative carboxylation of isocitrate to alfa-keto-glutarate producing 
nicotinamide adenine dinucleotide phosphate (NADPH). Two of these have been 
found to be mutated in GBM; IDH1 and IDH2. Both have the same mutagenic 
effect, and both are validated as prognostic markers for GBM as well as LGG. 
IDH is found mutated in about 5% of primary GBM and up to 70% in secondary 
GBM and LGG 29,30. 
Further, characterization of genetic pathways has resulted in GBM being subdivided 
into primary (de novo) developing through multistep tumorigeneses, and those that 
are secondary, developing through progression from LGG such as astrocytoma 
or oligodendrogliomas 31-34. Primary (de novo) GBM are more frequent in older 
patients, while secondary GBM occur more frequently in younger individuals. 
Genetically, these two entities carry distinct alterations; TP53 mutations, 19q loss 
are typical in secondary GBM – while EGFR amplifications, chromosome 10 loss 
and PTEN mutation are more often seen in primary GBM (Figure 2). 
4Also, more recent genetic profiling has even subdivided GBM further into four 
different subtypes; classical, proneural, neural, and mesenchymal (Figure 2). Each 
of these has a genetic signature from distinct neural lineages, implying that the 
expression patterns of the different subtypes may reflect the phenotype of their 
specific cells of origin 32,33. The classical subtype is synonymous with high EGFR 
expression, loss of heterozygosity (LOH) in chromosome 10 is frequently seen as 
is chromosome 7 amplification. On the other hand, TP53 which is often mutated 
in GBM, but is rarely mutated in this phenotype. CDKN2A is often deleted which 
in turn causes inactivation of the Retinoblastoma (Rb) pathway 35. The mesen-
chymal subtype is synonymous with mutations and alterations in the NF1 gene, 
while having fever alterations- and less expression of EGFR than the other three 
phenotypes. Also, mutations are seen in PTEN which in turn activates the RAS 
pathway 32,33. The proneural subtype, often secondary GBMs, is synonymous with 
high rates of alterations in TP53, IDH1 and PDGFRA (which activates the PI3K 
and RAS pathways). And finally, the neural subtype, often histopathologically 
classified as ‘normal brain tissue’, is synonymous with expression of neuronal 
markers. Nevertheless, this subdivision, although promising and certainly over-
coming some of the heterogeneity in GBM, has currently no role in diagnostics 
and treatment decisions. 
Figure 2. Glioblastoma carcinogenesis and relevant molecular alterations, from 36.
5Finally, O6-methylguanine DNA methyltransferase (MGMT), a gene encoding a 
DNA repair enzyme, has recently been found to be of high prognostic value when 
methylated, since methylation silences DNA transcription, and thus expression 
of the MGMT enzyme. Since MGMT can repair only one DNA alkylation lesion 
due to its suicide repair mechanism, methylation of the MGMT gene promotor 
robustly affects DNA-repair capacity 37, which in turn leads to improved prognosis 
(improved response) when patients are treated with a DNA-alkylating agent such 
as Temozolomide (TMZ) 17. Nevertheless, 60-65% of our patients have an active 
MGMT enzyme and therefore respond poorly to temozolomide treatment, the main-
stay treatment for GBM patients. 
1.1.3 Glioblastoma stem-like cells
Recently, a high abundance of cancer cells with stem-like properties have been 
discovered in several cancer forms, named cancer stem-like cells, or more specifi-
cally in GBM the Glioma Stem Cells (GSC) 34,38-41. The GSC are believed to pos-
sess self-renewal and multipotent differentiation abilities, contributing to resistance 
to conventional treatments, high recurrence rate and high heterogeneity of GBM.   
In terms of mechanism of action, GSC have after irradiation shown to activate the 
DNA Damage Response (DDR) – by activation of ATM, Chk1 and Chk2 – resulting 
in efficient checkpoint-mediated delay in cell cycle progression to allow active DNA 
Repair and thus recovery and later recurrent growth of GSC 42. Notch signaling is 
another key aspect of GSC biology – often upregulated and promoting self-renewal, 
while downregulation of Notch increases radio sensitivity 43. STAT3, involved in cell 
growth, immunoregulation, cell division and apoptosis is also overexpressed in GBM 
and GSC where it promotes cell growth and immunosuppression 44. Transcription 
factors such as sex determining region Y-Box (SOX2), octamer-binding transcrip-
tion factor 4 (OCT4), Polycomb complex protein (BMI1) and Nanog homeobox 
(NANOG) are also known to contribute to the stemness properties of CSC 45, analo-
gous to normal neural stem cells, maintaining self-renewal and undifferentiation as 
well an ensuring pluripotency.  
In terms of surface markers of GSC, Prominin 1 (CD133) is the one most widely 
recognized, also to be found on the surface of normal neural stem cells, and although 
the specific role of CD133 is yet to be demonstrated, it was shown to be of prognostic 
value for some GBM patients 46, with highest concentration of CD133 positive GSC 
found in the mesenchymal subtype which is highly resistant to radiotherapy and has 
the poorest prognosis 47,48. CD133 positive GSC form spheres when grown under 
conditions permitting stem cell proliferation, with each sphere thought to originate 
from a single GSC 49. GSC give rise to more differentiated daughter cells with higher 
proliferative capacities, contributing to the heterogeneity of the tumor and to tumor 
recurrence after radio- and chemotherapy 50, which is also confirmed by an increase 
6of CD133+ cells in glioma xenografts subjected to radiation, suggesting selective 
survival of GSC. The silencing of CD133 in GBM inhibits self-maintenance (i.e. 
inhibiting sphere formation) of GSC 51, further strengthening the hypothesis above. 
Furthermore, GBM is known for its rich vasculature, with GSC believed to reside 
near endothelial cells, with easy access to nutrients and signaling ensuring their 
undifferentiated state. This notion is supported by anti-angiogenic drugs inhibiting 
GSC population and tumor growth 52, and by the fact that endothelial cells release 
nitric oxide (NO), which has been shown to maintain GSC through the Notch 
signaling pathway known to contribute to GBM therapy resistance 53.
Also, we have recently shown that another clinical aspect of GBM treatment, the 
glucocorticoids administered to GBM patients, result in a stem cell phenotype 
promotion with increased resistance to chemotherapy in an in vitro model. These 
observations were substantiated with clinical data demonstrating decreased sur-
vival correlating to high glucocorticoid administration 54.
All the above mechanisms contribute to the hypothesis that GSC contribute to the 
therapy resistance of GBM, previously described by us and others as part of the 
key concepts in Glioblastoma therapy, making GSC a potential target for future 
therapies 55. 
1.1.4 Treatment 
Current treatment strategy of GBM consists of a combination of surgery, radio- 
and chemotherapy, that can prolong OS of a GBM patient up to a medium of 16 
months compared to medium 3 months OS if left untreated 16,17. 
In terms of surgery, there is increasing evidence that gross total resection (GTR) of 
more than 90% of the tumor mass results in improved one-year survival compared 
to those with subtotal resection (< 90% of the tumor mass removed) 56,57. This leads 
the research into new technologies that can help the surgeon achieve a GTR safely, 
such as operational microscope, micro instruments and recently even fluorescent 
dye in the form of 5-aminolevulinc acid (5-ALA) which stimulates synthesis and 
accumulation of porphyrins in malignant tissue, making it easily discoverable by 
the surgeon while looking under a microscope with an ultraviolet filter and result-
ing in GTR in 65% vs. 36% of GBM patients in a recent randomized study 58. 
In terms of radio- and chemotherapy, current treatment protocol (part of the Stupp 
regimen17) consists of fractionated radiotherapy post GTR in 30 fractions a 2 Gray 
(Gy) resulting in a total of 60 Gy, concomitant with chemotherapy in the form of 
TMZ. This combined regimen demonstrated a significant 2- and 5-year survival 
benefit in a recent large multinational trial 18, albeit still very poor. 
71.2 Medulloblastoma (MB)
Medulloblastoma (MB) is the most common primary malignant brain tumor in 
children. As is the case with GBM, despite intensive research for several decades, 
MB biology is still not fully understood, with the disease characterized by aggres-
sive tumor growth, dissemination through the cerebrospinal fluid, poor response to 
therapy and overall dismal prognosis.
1.2.1 Epidemiology
Medulloblastoma is a primary malignant brain tumor found in adults and children 
at a 10:1 ratio, with an incidence of 0,8/100.000 of at-risk children/year. MB is the 
most common malignant brain tumor in children, and the second-most frequent 
brain tumor in children after pilocytic astrocytoma 59,60. MB accounts for up to 20% 
of primary CNS neoplasms and approximately 40% of all posterior fossa tumors in 
children. Also, MB are seen more often in younger- than older children, with 40% 
of patients diagnosed before the age of five 59,60. In adults, MB is very rare – com-
prising less than 2% of CNS malignancies 60. 
Posterior fossa (cerebellum, brain stem and ventricles) is the predominant tumor 
location in most cases (90-95%), with occasional dissemination via the cerebro-
spinal fluid (CSF).  
To date, there is no specific risk factor that can explain most CNS malignancies in 
children, although some hereditary conditions show some association – including 
neurofibromatosis type 1 (NF1) and tuberculous sclerosis. Also, even though there 
is a slight association with increased familiar inheritance, it is not consistent. The 
only clear association has been shown for exposure to ionizing radiation (although 
this association is mostly historical in nature) and towards male sex, where MB is 
predominantly seen (62% vs. 38% in females), although this is only seen in  children, 
not in adults 59.
CNS tumors have one of the highest incidence rates among cancer in children 
and represent the second-most common cause of death from child cancer 61. With 
aggressive surgery, craniospinal radiotherapy and chemotherapy, more than 50% of 
children with medulloblastoma can be expected to be free of disease 5 years later. 
Nevertheless, the younger the patient is at diagnosis, the worse the prognosis is, 
with 10-year survival at 48% in those < 1-years old 60.
1.2.2 Pathogenesis and Classification
Pathogenesis
Embryonal tumors (tumors developing from embryonic cells, i.e. medulloblastoma) 
are all thought to arise from a common precursor cell of the subependymal matrix 
8in the CNS, nevertheless, as is the case with glioma, this subject is still heavily 
debated, and several cells are believed to be the possible “cells of origin”, includ-
ing cells of the subependymal layer, external granule layer (EGL), and internal 
granule layer (IGL). Recent advances targeting the granular cell progenitors 
(GCP) have revealed subpopulations of cells with distinct properties believed to 
be contributing to different subgroups of MBs 62,63 – i.e. GCPs from EGL are seen 
to have SHH mutations, while GCPs in the lower rhombic part of the cerebellum 
have an activated WNT signaling. Further, large scale studies as is the GENSAT 
project 64 have shown differences in GCPs at different developmental stages, 
raising the possibility that these are not a homogenous population as previously 
believed, but rather represent multiple progenitors with individual capabilities 
and thus different possibilities of tumorigenesis. Nevertheless, further research 
including genetic mapping is needed to identify specific GCP subsets responsible 
for the different subtypes of MB.
Classification
Besides MB, the group termed “embryonal tumors” includes traditionally atypical 
teratoid/rhabdoid tumors (ATRT), pineoblastoma, ependymoblastoma, cerebral 
neuroblastoma, ganglioneuroblastoma, medulloepithelioma and supratentorial 
embryonal tumor. Nevertheless, the newly updated WHO classification 26 has 
abandoned some of the traditional classification based only on histology and incor-
porated molecular data in the new classification. Although in the case of MB, a 
high-grade (WHO grade IV) embryonal neuroepithelial tumor, rather than having 
a great number of histological-molecular combination, “genetically defined” and 
“histologically defined” variants have emerged. In the “histologically defined” 
group, the classic, desmoplastic/nodular, large cell/anaplastic and MB with 
extensive nodularity have been included. In the “genetically defined” group, MB 
WNT-activated, MB SHH-activated and TP-53 mutated, MB SHH-activated and 
TP-53 wildtype as well as MB non-WNT/non-SHH (group 3 and group 4) have 
been included. Further, those unable to classify as any of the above, a not other-
wise specified classification has been made available (Medulloblastoma NOS). 
As to the molecular markers/genetically defined subgroups, four main subgroups 
have been agreed upon; WNT, SHH, Group 3 and Group 4 (Figure 3).
WNT is the rarest subgroup accounting for approximately 10% of all MB, typically 
presenting with somatic mutations in the CTNNB1 gene encoding beta-catenin, 
which in turn leads to an overexpression in the WNT signaling pathway 63. These are 
rarely metastatic and have a favorable outcome compared to the other subgroups 65.
SHH accounts for approximately 30% of all MB, with often seen mutations in the 
tumor suppressor genes SMO, SUFU and PTCH1 – or amplification of GLI2 or 
MYCN, resulting in overexpression of the SHH signaling pathway. Further, TP53 
9mutation seen in approximately 20% defines poorer prognosis in this subgroup, 
which otherwise has an intermediate prognosis. 20% of patients have metastatic 
disease at presentation. 
Group 3 represents 25% of all MB, and although no specific pathway has been 
found to be overexpressed (ergo the name Group 3), a frequent MYC amplification 
and isochromosome 17q alteration. These patients have the worst outcome, and 
present with meningeal dissemination in almost half the cases at time of diagnosis 66.
Group 4 accounts for most cases, while being the one least defined, without any spe-
cific pathway found to be overexpressed (ergo the name Group 4). Isochromosome 
17q alteration and MYCN amplification (as in group 3) are often found, besides 
some other cytogenetic alterations. Group 4 patients often present with metastatic 
disease at diagnosis, although their prognosis is better than of those classified in 
Group 3. 
Figure 3. Medulloblastoma molecular markers/genetically defined subgroups; WNT, SHH, 
Group 3 and Group 4, from 67. 
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The pathologist generates an integrated diagnosis considering both the “histologi-
cally”- and “genetically” defined groups, which can then be used for treatment 
guidance and risk stratification. The current risk stratification for patients between 
3-17 years divides risk classes into “low risk”, “standard risk”, “high risk” and 
“very high risk” defining outcome (survival). As such SHH p53 mutated and Grade 
3 metastatic and MYC amplified tumors are found on one side of the spectrum 
(very high risk), while WNT non-metastatic are found on the other side of the 
spectrum (low risk). This risk stratification helps guiding clinicians in how to treat 
and inform their patients, i.e. raise the possibility to try more aggressive drugs in 
patients with otherwise poor prognosis, and/or use less aggressive treatment in 
those with a good prognosis 67. 
1.2.3 Medulloblastoma stem-like cells
As in GBM, cancer cells with properties like stem cells (so called cancer stem-like 
cells) have also been discovered in MB and are often referred to as Medulloblastoma 
Stem Cells (MBSC). These cells are characterized mainly by their CD133 and/or 
CD15 positivity which has been proposed to sort and identify MBSC. MBSC are 
believed to possess self-renewal and multipotent differentiation abilities, confer-
ring resistance to radio- and chemotherapy, high recurrence rate and heterogeneity 
of MB. Although less is known about the detailed molecular pathways of MBSC 
in comparison to GCS, the following are key mechanisms often mentioned when 
discussing stemness and therapeutic resistance; 
In terms of therapeutic resistance, activated PI3K/Akt signaling pathway and sec-
ondary p53 mediated cell-cycle arrest has been found in MBSC after irradiation 
68. This transient p53 induction (propagated through the phosphatase and tensin 
homologue (PTEN)), enables these cells to reenter the cell cycle later, and as such, 
inhibition of this signaling pathway (PI3K/Akt) in turn decreases this possibility 
and sensitizes MBSC to irradiation. 
In terms of stemness, 2 key mechanisms are often mentioned as contributors; the 
Notch signaling pathway and the Shh signaling pathway. The Notch signaling path-
way, upregulated in MBSC as well as normal brain stem-cells, which if inhibited 
by the gamma-secretase inhibitors, results in a decrease of CD133 positive MB 
cells 69,70. Further, it has been shown that hypoxia, through HIF-1alfa stabilization 
maintains Notch 1 and stem cell phenotype in MB 71. These different mechanisms 
of action, all propagated through Notch, demonstrate a central role of this pathway 
for MBSC stemness. As to the Shh signaling pathway, it has been reported that an 
increased Shh pathway activation results in proliferation of CD15 positive MBSC 
and tumorigenesis in MB 72. To corroborate the importance of the Shh pathway in 
MBSC stemness, it has been shown that Gli1/2, the main transcription factors in 
the SHH pathway, interact with stem-related factors such as MYC-N, Nanog and 
Bmi1 in the self-renewal regulation of MBSC 73,74
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In general, as in GSC, MBSC are believed to contribute to therapy resistance, with 
MB patients harboring large number of MBSC having poorer prognosis 38,75,76, thus 
making MBSC a target for future therapies. 
1.2.4 Treatment
Current treatment strategy for MB in adults and children aged 3 and above consists 
of aggressive surgical resection followed by radiotherapy (craniospinal irradia-
tion) and chemotherapy resulting in a cure rate of up to 70% 77,78. Although this 
regimen carries a risk of treatment related toxicity with non-negligible risk of 
affecting quality of life 79-82.  
As with GBM, surgical resection aiming at GTR (in medulloblastoma less than 
1,5 cc tumor residual) has been the cornerstone of MB treatment for decades, which 
has with continuous technical advances decreased the current surgical mortality 
down to < 1% 83. Traditionally, to be classed as a “standard risk” MB patient, a 
successful GTR had to be performed. Historically, patients without GTR have had 
a poorer outcome 84, although recent studies analyzing the importance of extent 
of resection taking molecular markers into account did not show any benefit in 
GTR above sub-total resection (STR, more than 1,5 cc tumor residual) in overall 
survival, regardless of subgroup 85. Further, there was no benefit in terms of sur-
vival- or progression-free survival in those with near-total versus GTR 85, ultimately 
leading to the recommendation of maximal safe-resection without any apparent 
clinical benefit of surgical removal of small volume residual disease that carries 
a high risk of neurological morbidity 85. Morbidity wise, the most notable risk is 
the risk of cerebellar mutism syndrome, which approximately 25% of patients 
develop after surgery 82, resulting in speech difficulties, hypotonia and ataxia. The 
difficulties usually last weeks to months but can sometimes even be permanent 82.
In terms of radio- and chemotherapy, patients are now treated differently depending 
mainly on the “risk” classification and age. Thus, patients > 3-5 years classed as 
“average” risk are most often treated with 23.4 Gy craniospinal irradiation (adults 
typically receive 36 Gy) with a boost of 55 Gy to the tumor bed, followed by cyto-
toxic chemotherapy 86,87, while those classed as “high” risk are treated with a higher 
dose of craniospinal irradiation, 36-39 Gy. Patients < 3-5 years of age are treated 
with radiotherapy sparing approaches due to the high risk of serious neurocogni-
tive and endocrine side-effects 88,89. The chemotherapy regimens typically consist 
of cisplatin/carboplatin-vincristine-cyclophosphamide, albeit even methotrexate 
(intravenous and intrathecal/ventricular) and autologous hematopoietic cell rescue 
have been used in more “high” risk cases 90.
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1.3 Cell cycle and checkpoint control
Cell proliferation is a fundamental feature of life, the basis of which at the single cell 
level is the cell division cycle (cell cycle for short), a process that must be very tightly 
regulated to avoid pathologies such as developmental defects (under-proliferation) 
or cancer (uncontrolled/excessive proliferation). The two critical events during each 
cell cycle are: i) the duplication of the genome during the DNA synthesis phase 
(S phase) and ii) the formation of two daughter cells through cell division at mito-
sis (M phase). The M and S phases are separated by two other, largely regulatory 
phases G1and G2, overall in the sequence: G1-S-G2-M (Figure 4). Cells that are 
not proliferating, are commonly referred to as being in a so-called quiescence state 
(G0 phase). There are many proteins that participate and coordinately control the 
order, timing and quality of the cell cycle events, however the two major engines 
that drive the progression through the cell cycle stages are cyclin-dependent kinase 
complexes (CDK1 with cyclin B, CDK2 with cyclins A or E, and CDK4 and CDK6 
with D-type cyclins), and ubiquitin ligases Skp, Cullin, F-box containing complex 
(SCF) and Anaphase-promoting complex (APC) which timely degrade some cyc-
lins and other regulatory proteins in G1, S or M phases, respectively (Figure 4). 
Additional important elements of the cell cycle control machinery include two 
families of negative regulators known as CDK inhibitors (the ink4 family: p15, 
p16, p18 and p19; and the Cip/kip family: p21, p27 and p57) and various posi-
tive regulators that activate the cyclin/CDK complexes at the desired times and 
transitions during the cell cycle, such as the Wee1 kinase or the CDC25 family of 
phosphatases: CDC25A, B and C (Figure 4). Supra-imposed on the basic cell cycle 
machinery are two layers of the so-called checkpoints, mechanisms that ensure 
the proper duration and quality of the cell cycle steps. Examples of the first type 
of checkpoint mechanisms include e.g.: a) the so-called restriction point (R point) 
in late G1 that allows the entry into S phase only when proper growth factors and 
mitogenic stimuli are available, and b) the regulatory steps around mitosis, such as 
the mitotic spindle checkpoint that controls the proper alignment and separation of 
the mitotic chromosomes. The molecular basis of the R-point mechanism reflects 
mitogenic signals that activate the cyclin D-CDK4/6 complexes which then phos-
phorylate the pRB tumor suppressor, thereby releasing the E2F transcription factor 
and activating a range of genes that allow progression into S phase and completion 
of the cell division cycle (Figure 4). Apart from these intrinsic cell cycle check-
points, another layer of control encompasses mechanisms that sense and respond 
to insults such as DNA damage, and through a cascade of kinases can activate the 
p53-p21 checkpoint and other elements that can transiently delay or block the key 
cell cycle transitions to allow time for DNA repair or prevent cell division with 
damaged chromosomes (the G1/S, intra-S and G2/M checkpoints, respectively). 
More details about these DDR checkpoints including the kinase cascades involved 
and the effector pathways, are presented in the section 4.2 focusing on the DDR 
machinery.
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Figure 4. Cell Cycle regulation mechanisms, from 91.
1.3.1 Genomic instability, DNA damage response (DDR) and 
tumorigenesis
Both exogenous and endogenous events or insults, such as faulty DNA replica-
tion, ionizing- and ultraviolet radiation and genotoxic substances such as meta-
bolic reactive oxygen species (ROS) can result in the formation of diverse DNA 
lesions, which, if left unrepaired or mis-repaired, can cause genomic instability. 
Depending on the type of cells involved (Germ cells vs. somatic cells) the genomic 
location of mutations, extent and timing, the genomic instability may predispose 
to (hereditary) or contribute to initiation or progression (somatic) of cancer 92. In 
the last decade or so, novel molecular techniques and cancer genome analysis have 
provided new insights into genomic instability and its roles in tumor evolution as 
well as response to treatment. The wide spectrum of alterations on a genetic level 
that together represent the genomic instability and can contribute to tumorigenesis 
include for example subtle (often point) mutations or chromosomal abnormalities 
such as deletion-, amplification- or rearrangements of chromosome segments or 
even gain(s) or loss(es) of whole chromosomes. The latter more gross chromosomal 
alterations are often referred to as chromosomal instability (CIN) and lead to the 
state of cancer cells with altered chromosome numbers or structure ( aneuploidy). 
Along with epigenetic changes, the mutations and chromosomal aberrations lead 
to activation of oncogenes or loss of tumor suppressors, collectively driving 
tumorigenesis.
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In the presence of DNA lesions, an otherwise healthy cell responds by activat-
ing the DNA damage response. If unable to repair the lesions, cells will either 
prematurely stop proliferating (cellular senescence) or undergo cell death, often 
by apoptosis. As such, the DNA Damage Response (DDR) mechanism(s) is a 
safeguarding network that senses the presence of single- and double strand DNA 
breaks, modifications of incorporated nucleotides or aberrant replication fork 
structures, as well as alterations in higher-order chromatin structure – which all 
can lead to DDR activation, resulting in activation of cell cycle checkpoints, DNA 
repair mechanisms and other responses, potentially including apoptosis 93. These 
mechanisms are crucial for maintaining genome integrity, and thereby preventing 
genetic diseases including cancer 94.
As briefly eluded to above, it is important to distinguish between hereditary- and 
non-hereditary (sporadic) cancers. Hereditary cancers are the consequence of 
mutations in the germ-line, often affecting DNA repair or checkpoint genes, while 
the non-hereditary cancers reflect mutations acquired by somatic cells during the 
lifespan. According to the so-called mutator hypothesis (not generally accepted, 
however), the initial instability seen already in early precancerous lesions will pro-
gressively lead to increase in the spontaneous mutation rate, thus driving tumori-
genesis 95,96. Among examples of hereditary cancers are the mutations in breast 
cancer susceptibility genes (BRCA1 and BRCA2) which are linked to homologous 
recombination repair of DNA double strand breaks (DSB), or those mutations that 
inactivate components of the DNA mismatch repair pathway associated with colon 
cancer (HNPCC/Lynch Syndrome) and endometrial cancer. The germline muta-
tions are present in every cell in the body, they are largely recessive, and therefore 
they often manifest fully only when the other allele gets deleted or affected by 
another mutation in the incipient tumor cells. On the other hand, when it comes 
to non-hereditary cancers (sporadic), the molecular basis is more variable, there is 
currently no evidence of any uniform pathway, albeit it is believed that the major 
contributor to genomic instability is DNA replication stress as discussed in more 
detail below 97. 
In general, one can argue that cellular DNA is under constant attack from both 
endogenous and exogenous genotoxic insults. As such, even a task as “simple” 
as maintaining a “healthy” genome requires a repair of more than 10 000 DNA 
lesions per day 98. For this purpose, cells have a sophisticated DNA damage response 
(DDR) machinery in place, with many proteins that sense the diverse types of 
DNA lesions, initiate signaling pathways that result in activation of checkpoints to 
assure that damaged DNA is not replicated, and affect many aspects of cell func-
tion 99,100. The checkpoint activation and subsequent effector mechanisms depend 
on the nature of the damage and cell cycle phase. 
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1.3.2 The cellular DDR machinery
From a simplified point of view, DNA lesions are found in the form of 1) damaged 
bases, 2) mis incorporated bases, 3) single strand breaks (SSB), 4) double strand 
breaks (DSB) and the recently recognized 5) obstacles to DNA replication forks 
(generally defined as replication stress, discussed separately under 4.3). Depending 
on the lesion type, different mechanisms are responsible for the response and action 
in terms of DNA repair: 1) Damaged bases are removed either by nucleotide exci-
sion repair (NER) (extra bases added after e.g UV exposure) or base excision repair 
(BER) (in case of alkylated or oxidized bases), while mis-incorporated bases are 
removed by mismatch repair (MMR).
The signaling from lesions to diverse checkpoint and repair processes is initiated 
by activation of different kinases, of which phosphatidylinositol-3-kinase like 
family (PIKK), including ataxia-telangiectasia Rad-3 related (ATR) and ataxia-
telangiectasia mutated (ATM) as central signal transducers (Figure 5). Whereas 
ATM (and another important PIKK member, DNAPKcs) primarily respond to 
DSBs (and operate throughout the cell cycle), ATR is responding to various forms 
of damage during DNA replication, often coupled to single strand DNA breaks and 
stalled replication forks in S-G2 phases. Together with the effector kinases Chk1 
and Chk2, the major signaling modules ATR-Chk1 and ATM-Chk2 then phospho-
rylate hundreds of cellular proteins and thereby trigger the overall multifaceted cel-
lular DNA damage response 94, eventually leading to cell cycle delay, DNA repair, 
chromatin modulation, transcriptional and metabolic changes, overall designed to 
survive and repair the damage, or, in case the damage is too severe or irreparable, 
to permanently arrest or eliminate such potentially unstable cells (Figure 5). For 
example, the cell cycle delay or arrest are caused by phosphorylation of p53 by the 
above-mentioned DDR kinases, and thus activation of the p53-p21 axis that blocks 
the activity of some CDKs, or by degradation/inhibition of the cell cycle-activating 
CDC25 phosphatases, again through phosphorylations mainly by the effector kinases 
Chk1 and Chk2. In terms of chromatin response, the ATM (recruited by the MRN 
complex that senses DSBs), ATR and DNAPKcs kinases can each phosphorylate 
histone H2AX near DNA breaks, and such modified histone (called gammaH2AX) 
then serves as a starting point to recruit a cascade of DNA repair proteins (including 
e.g. the 53BP1, Figure 5). In addition, detection of gammaH2AX by antibodies 
provides a robust marker for overall DNA damage signaling and, if observed in the 
form of nuclear foci, this marker provides a surrogate for genomic DNA double 
strand breaks in that cell, or in a clinical specimen. 
As indicated above, one prominent substrate of DDR checkpoints is p53, whose 
activity and abundance increases due to protein stabilization, with the ensuing broad 
transcriptional response driven by p53. Apart from such moderate and widely cell-
to-cell variable increase in p53 abundance, p53 is very frequently mutated in cancer 
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and the point-mutant forms are commonly very stable, providing a helpful sur-
rogate marker for p53 mutation even when analyzed by immunohistochemistry in 
archival paraffin samples. This is a very frequent event that is selected for in cancer 
progression, providing a way for cancer cells to escape the p53-mediated cell death 
or senescence that is otherwise triggered upon DDR signaling to p53 under condi-
tions of oncogene-induced replication stress or DNA damage. Overall, these and 
additional antibody-detected markers (such as the 8-oxoguanine (8-OXO) lesion 
reflecting oxidative DNA damage, relevant for the studies presented in this thesis) 
can be followed in both clinical samples and cell culture models, and allowed us 
to obtain a large amount of information about human brain tumors, in this context 
especially in relation to HCMV, replication stress and stemness phenotypes, and 
about features important for tumor evolution and responses to treatment 94,101,102. 
Figure 5. Cell cycle checkpoint induction through the DDR network, from 103.
1.3.3 DNA Replication stress (RS): an emerging hallmark 
of cancer
DNA replication stress is currently defined in broader terms as any obstacles or 
deregulation of DNA replication process that alter progression and/or fidelity of 
DNA replication forks. Accumulating evidence indicates that replication stress 
(RS) represents a very common phenomenon shared by almost all cancer types, 
leading to a proposed candidacy of RS as an emerging hallmark of cancer. This 
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concept postulates that activated oncogenes or loss of some tumor suppressors 
responsible for deregulated cell proliferation and DNA synthesis induce DNA rep-
lication stress early in the tumor evolution - often in the preinvasive early lesions. 
The RS triggers activation of checkpoints responses including the p53, and in this 
way the activated DDR machinery provides a biological barrier against further 
tumor progression, mostly leading to cell cycle arrest/senescence or apoptosis. 
However, this stressful environment under RS at the same time creates conditions 
for selecting mutations such as in p53 or other DDR checkpoint genes, eventually 
allowing escape of rare tumor cells from the DDR checkpoints, allowing for cell 
proliferation and at the same time enhancing genomic instability, which in turn 
fuels tumor progression and impacts responses to treatment 104. 
At the level of replication forks, RS can result in “replication fork stalling” or 
even fork collapse, the latter then leading to creation of DNA breaks or even cell 
death, unless prevented by control mechanisms of cell cycle progression. These 
include mainly S-phase checkpoint responses dependent on the RPA-ATR-Chk1 
axis that becomes activated by excessive stretches of single-stranded DNA that 
form during RS. The ATR signaling prevents new DNA replication origins from 
‘firing’, at the same time stabilizing the affected replication forks and preventing 
fork collapse. The stalled forks can be repaired by the homologous recombination 
repair mechanisms that include also the BRCA1/2 proteins and re-started, thereby 
resuming normal DNA synthesis and ensuring satisfactory replication completion. 
During tumorigenesis, more severe replication stress conditions can be triggered 
by diverse oncogenes or loss of tumor suppressors, triggering the DDR anti-cancer 
barrier as mentioned above, to ensure genome integrity 93. 
As in case of DNA lesions caused by other insults (i.e. ionizing or UV radiation), 
DDR mechanisms that respond to RS ensure maintenance of genome integrity by 
making sure “damaged” cells are either brought to a state of senescence or forced 
into apoptosis 105. Consequently, a non/dys-functional DDR machinery results in 
genomic instability and potential progression of tumorigenesis 105. In summary, 
while hereditary cancers often result from germ-line mutations in DNA repair 
genes, in non-hereditary cancers, it is commonly the oncogene induced replication 
stress that is believed to fuel genomic instability and the process of tumorigenesis. 
1.3.4 Viruses and the DNA damage response
Recent evidence in the fields of DNA Damage and Virology has demonstrated 
that mammalian viruses (such as HCMV) use different strategies to disturb host 
defense systems, including altering the DDR in the host – to facilitate viral rep-
lication. More specifically, DNA viruses have been shown to induce and subvert 
the DDR 106. RNA viruses may also induce DDR, albeit the mechanism by which 
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RNA viruses affect the DDR might be indirect. The mechanism through which 
viruses activate the DDR is usually mediated through the DSB signaling pathways. 
For example, certain oncoproteins of DNA viruses such as papillomavirus E6 
and E7, simian virus Large T antigen or adenovirus E1a and E1b, disable the p53 
tumor suppressor or interact with the RB family of tumor suppressors in ways that 
result in E2F mediated cell cycle stimulation even in the absence of physiological 
growth stimuli. Such deregulation of DNA synthesis may lead to DNA breakage 
and activation of the ATM/ATR/DNAPKcs signaling pathways, favoring virus rep-
lication through virus-induced modulation in the host cell DDR 107. In general, the 
modulation of the DDR is somewhat different from virus to virus, but in all cases, 
it results in recruitment of host-cell DNA repair proteins to the viral replication 
compartments 108-111, which then aids the virus with the replication procedure. As 
such, i.e. EBV induces phosphorylation of ATM, H2AX, CHK2 and p53 during 
lytic infection, after which these are moved to the EBV replication compartments. 
As for the interaction between HCMV and DDR – please see chapter 1.5.1. 
1.4 Human Cytomegalovirus (HCMV) 
Human cytomegalovirus (HCMV), also known as human herpesvirus-5 (HHV-5), is 
a member of the Herpesviridae (Herpesvirus) family which is carried by 60-100% 
of the world’s population 112. Following an active primary infection, often asymp-
tomatic, the virus establishes latency in the bone marrow, mainly in the cells of 
myeloid lineage 113,114. 
HCMV structure
The structure of HCMV is typical of that of a herpes virus, being 200-300 nm in 
diameter, consisting of: i) icosahedral nucleocapsid surrounded by ii)  proteinaceous 
tegument and an iii) outer lipid bilayer membrane. The nucleocapsid proteins 
assemble into A, B and C capsids of which only one (C) contains the genome 
and can as such form a “mature” virion, while A and B form non-infectious parti-
cles 115. ii) The tegument is a protein layer surrounding the nuclear capsids before 
they become enveloped. It consists of more than 30 proteins, of which the ones 
with the highest concentration are pp65, pp71, pp28 and pp150. pp65 is the most 
abundant, mainly responsible for early immune system evasion 116 during infection, 
while pp28 is responsible for the cytoplasmic envelopment of tegument proteins 
during lytic infection 117. pp71 activates immediate early genes and as such viral 
replication during infection 118. Finally, pp150 is responsible for assembly of virus 
particles, as well as incorporation of nucleocapsids into these particles 118. iii) The 
outer bilayer (envelope) is assembled in the host cell after it has passed through 
the ER – in Golgi derived vesicles - and released through virus budding 119. It 
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contains more than 20 different viral glycoproteins (i.e. glycoprotein B (gB), gH, 
GM, GN), as well as glycoproteins from the host cell. These play an important role 
in the life-cycle and spread of the virus infection, where incorporated host glyco-
proteins contribute to the ability of the virus to spread without the hos immune 
system recognition 120. In the viral nucleocapsid, double stranded DNA is packed, 
which constitutes the HCMV genome, consisting of 235 kbp with 252 open read-
ing frames (ORF) 121. The HCMV genome however produces about 750 RNAs 121; 
most of these are not characterized. The genome is divided into regions named 
the long (UL) and short (US) – which also gives name to the respective HCMV 
genes and proteins 122.  Although the genome encodes for over 750 mRNAs, and 
likely but not yet defined, encode for hundreds of proteins, only about 50 of these 
are implied to have a role in the viral replication process, the rest are believed to 
function to aid the virus to coexist with its host 121. 
1.4.1 Replication and latency of HCMV
Replication
The HCMV replication takes place mainly in endothelial, epithelial cells and inflam-
matory activated macrophages, but the virus can also infect neutrophils, fibroblasts, 
smooth muscle cells (SMC) as well as neurons and glial cells 123. The virus utilizes 
surface glycoproteins gB and gH/gL which are essential for cell attachment 124. After 
attachment, the viral envelope fuses with the cell membrane leading to the release 
of nucleocapsids into the cytoplasm. These then travel through the cytoplasm and 
are eventually translocated into the nucleus, where the viral DNA is released. This 
leads to viral gene expression in the form of both immediate early (IE)-, early (E)- 
and late (L) genes, all of which involved in the process of viral replication. IE are 
produced first, and are responsible for the regulation of transcription, E genes are 
responsible for the viral DNA replication and L genes encode the structural proteins 
and as such appears last  in the replication cycle 125. The viral DNA is replicated via 
HCMVs own functional DNA polymerase in the host cell nucleus and within spe-
cial viral replication compartments, while the host RNA polymerase II transcribes 
all the HCMV genes 126. After the replication process is complete (approximately 
by 24-48 hours post infection), the viral DNA is packed into newly synthesized 
capsids and transported from the nucleus to the cytoplasm. During this process, 
it passes through the cytoplasm and the endoplasmatic reticulum (ER) acquir-
ing initially the lipid envelope and tegument proteins, and finally the secondary 
envelop ment before being released from the cell as a virion – a process that takes 
about 72 hours (Figure 6).
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Figure 6. Human cytomegalovirus (HCMV) life cycle, from 127.
Latency 
As is the case with the other herpes viridae, after primary infection, a life-long 
latency is established. For HCMV this mainly occurs in cells of the myeloid  lineage 
(i.e. in monocytes and granulocyte-macrophage progenitor cells) and the hemat-
opoietic cell population (CD34+) of the hosts bone marrow 128. Recent studies 
have shown that latency, previously thought to be a passive process, is in fact an 
active process, with different genes being transcribed during latency. For instance, 
several latency associated proteins are responsible for immune system redirection 
(US28 and ORF94) and evasion by decreasing the immune recognition (UL44 and 
UL144) and cmvIL-10 129. In general, the latent HCMV gene expression is somewhat 
hetero geneous, varying between different cell populations 130,131, implying that it is 
likely the local differences in the cellular milieu that are responsible for the different 
expression profiles. Further, it has been postulated that HCMV related non-coding 
RNAs are transcribed during latency 130, making sure that the host cell environ-
ment can be modulated to suit the latent infection, without attracting the attention 
of the immune system. Finally, it is important to keep in mind that latent HCMV 
can be reactivated by inflammation and stress, often mediated through the initial 
upregulation of TNFalfa, IFNgamma and GM-CSF 114 which in turn differentiate 
monocytes into dendritic cells or macrophages. This is important since not all cells 
permit viral replication – i.e. undifferentiated cells such as monocytes – wherefore 
it is not until the monocytes are differentiated to macrophages or dendritic cells 
that the virus is reactivated, and the replication can commence 128 
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1.4.2 HCMV epidemiology, transmission and clinical course 
Epidemiology
HCMV is generally viewed upon as a very common infection in the general popu-
lation worldwide, with a seroprevalence of 60-100%, although to a certain degree 
dependent on the socioeconomic status, geography 112 and patient age, with the 
seroprevalence increasing with age (up to 90% in the elderly) 132. 
Transmission
HCMV has been shown to be transmitted in body fluids exclusively. These include 
blood, urine and saliva as well as through unprotected sexual contact. Mother to 
child infection can either be passed along through an intrauterine infection (unborn 
child) or through breast milk (after child birth) 133.
The clinical course of the HCMV infection 
The clinical course varies mostly depending on whether the patient is immuno-
compromised or not. As such, the primary infection in the immunocompetent indi-
vidual is often subclinical, although in certain cases the patient does present with 
mononucleosis-like-symptoms such as fatigue, fever and headache - with even rare 
cases of adenopathy, hepato- and/or splenomegaly recorded. Mortality is almost 
never seen, although some cases have been recorded 134. When the active/lytic 
infection is over, the virus establishes latency in the bone marrow and circulate in 
the blood in cells of the myeloid lineage 113,114. Besides the symptomatology above, 
evidence has emerged on the presence and possible contributing role of HCMV in 
several other inflammatory diseases such as atherosclerosis, inflammatory bowel 
disease, rheumatoid arthritis, systemic lupus erythematosus and psoriasis 135-140. In 
principle, since HCMV is reactivated by inflammation, HCMV might represent 
an epiphenomenon in the above context, or be a contributing factor in the inflam-
matory process itself as it is able to induce inflammation via for example COX-2 
and 5-LO and production of pro-inflammatory cytokines. So far, no consensus 
has been established on this matter.
In the immunocompromised individuals, such as organ- and stem cell transplant 
patients, the infection can end in serious developing adverse events resulting in a 
high risk of morbidity but even mortality 133. The risk of morbidity and mortality 
has been inversely associated with the level of immunological competence – i.e. 
low immunological competence = higher risk of morbidity and mortality in terms 
of more severe symptoms from the HCMV infection itself, but also higher risk of 
secondary opportunistic bacterial and fungal infections 141. Due to this, i.e. organ 
transplant patients are often treated with antiviral prophylactic therapy (pre- and) 
post-transplantation to avoid the risk of active and potentially life threatening 
HCMV infection 142. This drug regimen also protects against long term effects 
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of HCMV such as chronic rejection and myocardial infarction. Another exposed 
patient category is HIV patients – who often are coinfected with HCMV – and at 
risk of developing HCMV promoted cardiovascular and cerebrovascular inflam-
matory diseases 143. Nowadays, anti-retroviral therapy targeting HIV makes sure 
that the patients CD4+ cell count stays above 50 cells/mm3; this almost eradicated 
HCMV retinitis and severe gastroenteritis cases, which previously caused major 
morbidity and mortality among HIV patients 144.
Finally, the congenital HCMV infection, seen in 0.2-3% of infants born in western 
countries, is most often asymptomatic, while petechial rash, hepato-splenomegaly, 
jaundice, chorioretinitis and neurological deficits such as microcephaly, sensori-
neural hearing loss and retardation is seen in those that are symptomatic 145, while 
hearing loss is common even in otherwise asymptomatic cases at birth, and may 
present after several years. 
1.4.3 Diagnosis of HCMV
Classically, HCMV infection was for a long time diagnosed thanks to the so-called 
“owl’s eye”, or intranuclear inclusion bodies, visible in tissue specimens through 
the microscope 146. However, direct microscopy has today been replaced by more 
advanced diagnostic methods such as a) serology, b) immunohistochemistry, 
c) quantitative nucleic acid testing (i.e. polymerase chain reaction, PCR) and d) in 
situ hybridization. 
a) Serological techniques are focused on the detection of antibodies, which can tell 
the examiner if the patient has a primary infection (IgM antibodies present) or 
if the patient has been infected previously (IgG antibodies present) and usually 
determined by Enzyme-linked immunosorbent assay (ELISA) 147. 
b) IHC uses antibodies to label different HCMV proteins, making it possible to 
easily detect virus infected cells under a microscope, with the advantage to 
distinguish- and co-localize these with other cellular proteins. It is important 
to note that the sensitivity and specificity of the antibodies commercially avail-
able varies greatly, necessitating optimization of the IHC protocols 146. This 
is in particularly important when detecting HCMV proteins in tumor tissues 
samples, as a regular IHC method need antigen retrieval steps for detecting 
HCMV proteins in these specimens.
c) Quantitative nucleic acid estimation by PCR is the most widely used technique 
for HCMV detection in the clinical setting 147, mainly thanks to the technique’s 
high sensitivity and specificity, as well as the quantitative output, making it 
easy to ascertain the viral load in patient samples, and to follow treatment 
responses after initiation of anti-viral therapy 147. 
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d) In situ hybridization (ISH) uses labeled complimentary DNA strand probe to 
detect specific HCMV DNA in areas of interest in a tissue sample i.e. HCMV 
nucleic acids detection in human brain tumor tissue. These can be labeled with 
biotin or fluorochromes making them easily visible under a light or fluorescent 
light (FISH) microscope, respectively 148. This technique can not define whether 
the virus is active or latent in the tissue specimens. 
1.4.4 Treatment of HCMV
The most widely used anti-HCMV treatment(s) available all target the viral 
DNA polymerase: i) Ganciclovir (GCV) and it´s oral prodrug ii) Valganciclovir, 
iii) Foscarnet and iv) Cidofovir. Besides drugs targeting the viral DNA polymerase, 
there are drugs in pipe-line with different HCMV targets, such as Maribavir and 
Letermovir, both dampering viral DNA synthesis, and both successfully imple-
mented when treating resistant HCMV strains 149,150. 
Of the drugs targeting DNA polymerase, i) GCV is the oldest available – and still 
the drug of choice when it comes to treatment of active HCMV infection. GCV, 
which is available in both tablet and intravenous formula, is an acyclic nucleoside 
analog of 2′-deoxyguanosine that is phosphorylated by the viral protein kinase 
UL97 into a biologically active triphosphate form that inhibits viral DNA syn-
thesis by acting as a nucleoside analogue to block the viral DNA polymerase 151. 
Although effective, mutations in the HCMV UL97 gene causing GCV resist-
ance have been observed 152. Further, even though known side-effects are rare, 
kidney and liver toxicity cases, as well as hematologic abnormalities have been 
reported 153. ii) Valganciclovir (VGCV) is the per oral pro-drug of GCV (available 
in tablet- and oral mixture form), most frequently used in transplant patients as 
an effective prophylaxis. VGCV metabolizes to the active form in the intestinal 
wall 153. iii) Foscarnet, available in intravenous formula only, is a pyrophosphate 
analogue, which does not require enzyme activation to exert its effect. Foscarnet 
is considered a second-line treatment to be used when GCV is not effective due 
to resistance. The side-effects of Foscarnet treatment include mainly nephrotox-
icity, which necessitates close monitoring of patients treated 154. iv) Cidofovir, an 
acyclic nucleoside phosphonate analogue, is only available in intravenous formula 
and is converted to its active form by cellular kinases 155. The main advantage of 
Cidofovir is its long intracellular half-life, that allows for enough treatment even 
in case of treatment delay 155. As with Foscarnet, nephrotoxicity is a known poten-
tial side-effect and Cidofovir is only used as a second line treatment in certain 
countries (not available in Sweden).  
Besides the above, there are currently immunoglobulin preparations (IVIG) avail-
able in the form of hyperimmunoglobulin’s HCMV IVIG (purified IgG from 
HCMV seropositive individuals) and standard immunoglobulins polyvalent IVIG 
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(from donors with unknown HCMV status) 156. Due to known side-effects such 
as venous thrombosis and the risk of other disease transmission through blood 
products, IVIG treatment is not used as standard treatment 156. Finally, HCMV 
vaccines, although promising treatment modalities, are still only under develop-
ment 157. Finally, the treatment of HCMV in context of brain cancer will be dis-
cussed more extensively in chapter 6.2.  
1.5 HCMV and (brain) cancer
HCMV and malignant primary brain tumors
Since the early 2000, reports have come out on the presence of HCMV proteins 
and nucleic acids in multiple solid tumors, such as cervix cancer, ovarian cancer, 
prostate cancer, breast cancer, colon cancer, sarcomas, medulloblastoma, neuro-
blastoma and malignant glioma 158,159. Nevertheless, since the focus of my thesis 
are primary brain tumors, these will be the focus of the following chapter on 
HCMV and brain cancer. 
After the initial discovery of a high prevalence of HCMV in glioblastoma, further 
research has led into the charting of more than 90% of patients shown to have an 
active HCMV infection in multiple malignant primary- as well as secondary brain 
tumors 148,160,161. As such, active HCMV infection has also been found in GBM and 
MB brain tumor tissue 161,162, while at the same time remaining absent or latent in 
non-brain tumor tissue from the same patients. Further, the levels of active HCMV 
infection have been found to be of prognostic value in terms of correlation between 
high HCMV infection positivity and decreased overall survival 162. Nevertheless, 
even though active HCMV was found in tumor cells, as well as in endothelial- and 
inflammatory cells within the tumor, infectious virus that could be cultured in vitro 
has so far not been obtained from any tumor sample. The question thus remains if 
this HCMV presence in any way contributes to the development of brain tumors, 
or if active HCMV infection simply represents an epiphenomenon. 
Viruses and cancer 
Today, the oncogenic (leading to neoplastic transformation) or oncomodulatory 
(modulating already neoplastic cells) role of certain viruses in tumorigenesis is 
undisputable; hepatitis C and B virus cause hepatocellular carcinoma 163, human 
papilloma virus (HPV) causes cervix and oropharyngeal carcinoma 164, Epstein 
Barr virus (EBV) contributing to nasopharyngeal carcinoma and Hodgkin´s lym-
phoma 165, HHV-8 virus contributing to Kaposi´s sarcoma 166, and human T-cell 
leukemia retrovirus (HTLV) is associated with T cell leukemia 167. About 20% of 
human cancers are caused by these viruses. As for HCMV, accumulating evidence 
demonstrating a link between cancer and persistent active HCMV infection 168, 
but this virus is also not considered as an oncogenic virus. The oncomodulatory 
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effect of HCMV is believed to be propagated through different viral effects post 
cell infection, but only rarely transformation of normal cells into cancer cells 
has been observed 168,169. In general, HCMV viral proteins are thought to affect 
cell cycle progression differently in different cells, depending on the cellular dif-
ferentiation level – believed to promote tumor growth without affecting the sur-
rounding non-tumor cells 170,171. In the context of the “hallmarks of cancer”, as 
defined by Hanahan and Weinberg 172, I will in the following sections go through 
the different aspects of HCMV in relation to; sustaining proliferative signaling, 
evading growth suppressors, avoiding immune destruction, enabling replicative 
immortality, tumor-promoting inflammation, activation of invasion and metastasis, 
inducing angiogenesis, genome instability and mutation, resisting cell death and 
deregulating cellular energetics. 
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Figure.7. The “hallmarks of cancer” and HCMV effectors, modified from 172.
Sustained proliferative signaling and evading growth suppressors
The most renown feature of cancer in general, is its ability to promote sustained 
proliferation, while this is otherwise strictly controlled by complex signaling 
mechanisms, mainly consisting of growth factors and cytokines. The two main 
pathways often dysfunctional and/or overexpressed in cancer are the MAPK- and 
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PI3K/AKT pathways, that have been shown to stimulate cell growth, proliferation 
and cell survival 173,174. In HCMV infected cells, a commonly seen feature is acti-
vation of the PI3K pathway, promoting cell proliferation while also initiating viral 
DNA replication 175. Similarly, the MAPK, is also activated by HCMV resulting in 
ensuring viral DNA replication 176. It has also been shown that HCMV infected GBM 
cells dysregulate Rb phosphorylation and p53 expression 171. Related to this, several 
regulatory proteins of HCMV, such as IE-1, pp71 and UL97 can inactivate pRb 
promoting cell cycle progression 103. Also, IE-1 and IE-2 are known to deregulate 
the cell cycle checkpoint controls by interacting with p53 suppressor proteins 103,177. 
Resisting cell death
Programmed cell death, or apoptosis, is essential for maintenance of body homeo-
stasis, making sure damaged cells die and are eliminated in an orderly fashion. 
This mechanism is believed to be activated by 2 different pathways, known under 
the terms extrinsic and intrinsic pathways – both leading to induction of cell death 
and caspase activation making sure the cell is degraded in an orderly fashion 178. In 
brief, the extrinsic pathway is initiated outside of the cell, propagating it signaling 
through the so-called cell death receptors such as TNF-alfa and FAS-ligand recep-
tor. Likewise, the intrinsic pathway is activated inside the cell itself, mainly due to 
signaling from DNA damage propagated through different proteins such as p53, Rb 
while being regulated by the Bcl-2 protein family. HCMV has several properties 
enabling it to inhibit apoptosis, thereby improving the survival of HCMV infected 
cells. As such, IE-1 and IE-2 block apoptosis mediated by TNF-alfa 179, IE-2 binds 
p53 and thus inhibits its activation 180 and UL36 and UL37 inhibit apoptosis by 
inhibiting caspase activation (blocking FAS-ligand mediated apoptosis cascade) 181 
and inhibition of the mitochondrial pro-apoptotic proteins Bax and Bac (inhibition 
of mitochondria mediated apoptosis), respectively, thereby conferring resistance to 
chemotherapy in chronically infected neuroblastoma cells 182. 
Enabling replicative immortality
Normal cells have usually a cell cycle consisting of multiple divisions, although 
eventually they all undergo senescence and die. The main actors controlling this 
delicate process are the pRb and p53 proteins, which if inhibited, can result in 
uncontrolled cell divisions 183. In this context, telomerase, an enzyme frequently 
expressed in tumors, makes sure to avoid any shortening of the telomeres, prevent-
ing senescence and ensuring endless replication ability 184. My research group has 
shown that the activation of telomerase and telomere lengthening through interac-
tion with the hTERT promotor is induced by IE-1 in HCMV infected cells, and 
IE-1 and hTERT was shown to be co-expressed in GBM cells 185. Also, in relation 
to the above paragraph on proliferation, HCMV expresses pp71 and UL97 – both 
involved in phosphorylation and secondary inactivation of the Rb family tumor 
suppressor proteins 186,187, modulating proliferation and survival of the infected cell. 
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Genome instability and mutation 
Another hallmark of cancer, called genomic instability and mutation, occurring 
in case of limitless divisions, as mutations accumulate in the cell genome leading 
to destabilization. The destabilization itself can then lead to further mutations in 
important cellular genes controlling gene amplification, deletion, chromosomal 
segment re-arrangements, gain- or loss of entire chromosomes and others. As 
such, mutations in p53, pRb and Bcl-2 are known as being responsible of driving 
several hallmarks of cancer 188, and described in the paragraphs above, HCMV 
interacts with all of these. Please see chapter 1.5.1 on HCMV and DNA Damage 
for further details.
Inducing angiogenesis 
Angiogenesis is one of the first acknowledged hallmarks of cancer, an essential 
component of tumor development and enlargement which carries the need for 
vascularization. The levels of pro-angiogenic (i.e. VEGF and basic fibroblast 
growth factor) and anti-angiogenic (i.e. thrombospondin-1) factors within the 
tumor change so that levels of pro-angiogenic factors increase whenever the tumor 
sees the need for angiogenesis, with significant impact on metastasis and overall 
tumor progression 172. In the context of HCMV, promotion of angiogenesis has been 
demonstrated earlier, with US28 mediated upregulation of VEGF and secondary 
induction of angiogenesis in GBM tumors by affecting endothelial cells 189. In our 
lab, we could show that the infected cells do not exhibit angiogenic properties, but 
rather promote this in noninfected cells around the infected one through a parac-
rine effect 190. Thrombospondins on the other hand, important for anti-angiogenic 
control, are downregulated in HCMV infected GBMs 191. 
Avoiding immune destruction
The loss of anti-tumor immune response in the tumor microenvironment is an 
important step in tumorigenesis, supported by data showing increasing number of 
newly diagnosed infection-related cancers such as EBV and Kaposis Sarcoma in 
immune-compromised individuals 192. In general, a defect in either the protective 
function of the immune system against tumor cells (host related) and/or the evasion 
of the tumor cells from an attack mounted by the immune system (cancer related) 
can result in a dysfunction in the proper immune response. Multiple mechanisms 
behind this have been charted, among the more prominent ones is the presence 
of immunosuppressive signaling and/or increased presence of immunoregula-
tory cells. An example of immunosuppressive signaling are cytokines such as 
IL-10, TGF-beta and PGE2 released from the tumor microenvironment 193, while 
an example of immunoregulatory cells are T regs, which are expressed in higher 
numbers in infected individuals and suppress cytotoxic lymphocyte function 194. 
HCMV inhibits the expression of HLA class I and class II molecules and antigen 
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presentation (US2, US3, US6, US11, IE-1), it controls T cell activation, inhibits NK 
cell activation (UL18, UL16), blocks interferon (IFN) signaling (pp65), protects 
cells from cytolytic peptides that are released from activated T and NK cells 195. 
HCMV also produces and controls cellular production of chemokines, cytokines 
and growth factors 196. These are examples of strategies that make infected cells 
invisible to the immune system and may explain why HCMV infected tumors are 
not controlled by the immune system and express variable response to immuno-
therapies developed against them, as infected tumor cells will be invisible to the 
immune system 197. 
Tumor-promoting inflammation
At the same time as the virus avoids immune recognition, it is dependent on 
inflammation.  Our group was first to identify cells of the myeloid lineage as the 
major circulating carriers of latent virus, and that immune activation of T cells and 
the consequent production of TNF-alfa and IFN-gamma, resulting in macrophage 
differentiation, is a key element in the reactivation of latent HCMV 114. HCMV 
also affects COX-2 and my research group found that the virus also induces 5-LO 
expression 198, which results in induced inflammation and enhanced virus replica-
tion with high relevance in tumor biology. In fact, in our recent work, only HCMV 
positive cells in medulloblastoma expressed COX-2 161.
It is well established that chronic inflammation both contributes- as well as pre-
disposes to cancer, with anti-inflammatory drugs such as aspirin linked to risk 
reduction of suffering from cancer, as well as lowering the risk of metastasis 199. 
As such, tumor micro environment including among other inflammatory cells (i.e. 
myeloid cells) and fibroblasts functions as a supportive matrix for tumor growth, 
potentiated by HCMV infection which resides in the inflammatory cells as well 
as in tumor cells, as has been shown in among other colon, breast and glioma 
patients 200 201. 
Similarly, Cyclooxygenase (COX) has been associated with poor survival in cancer 
patients when overexpressed 202, as has increased PGE2 203 – both of which have 
been target for recent trials with non-steroidal anti-inflammatory drugs such as 
COX inhibitors 204. Since COX inhibitors are also good anti-HCMV drugs, the 
effect observed in cancer patients may involve effects on HCMV. Also, our group 
has recently reported that HCMV infection in medulloblastoma induces COX-2 
expression, - with the COX-2 inhibitor in combination with Valganciclovir inhib-
iting HCMV replication and PGE2 production in vitro, with reduced cell- and 
tumor growth reported 161.
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Activation of invasion and metastasis
To metastasize, tumors must invade the supportive tissue around the tumor mass 
itself, and breach through to the blood- or lymphatic vessels. Then it must travel to 
a distant site, where it extravasates from the vessel and initiates cell division even-
tually forming a metastasis. In relation to HCMV, several studies have reported on 
the effect HCMV might have on promoting activation of invasion and metastasis; 
in prostate cancer, HCMV infection increased adhesion to the endothelium, lead-
ing to disruption in membrane integrity, aiding in tumor cell migration 205, while 
another group found that HCMV infected renal tubular epithelial cells underwent 
epithelial-mesenchymal transition, while increasing the expression of TGF-beta and 
MMP-2 – believed to be initiated by IE 206. When it comes to primary brain tumors, 
HCMV infection has been shown to increase tumor cell adhesion and migration 
through endothelial cells in neuroblastoma 207 and cell migration through US28 in 
glioma 208, possibly enhancing invasiveness. In a clinical context, our group has 
reported on HCMV being expressed in both colon- and breast cancer patients, in 
lymph node metastases and brain metastases with high-viral load being associated 
with shorter time to tumor progression and shorter survival. 
Deregulating cellular energetics
HCMV has been associated with several mechanisms involving cellular energet-
ics. The metabolic alterations observed in HCMV infected cells are strikingly 
like those observed in cancer cells and most likely influence on HCMV mediated 
oncomodulation. For example, i) HCMV induces the Warburg effect 209, enhances 
glycolysis, fatty acid synthesis and glutamine uptake. ii) HCMV stabilizes ATP 
production through binding of the non-coding RNA beta2.7 to complex I in the 
mitochondrial respiratory chain – and simultaneously inhibit apoptosis in HCMV 
infected glioma cells 182,  and iii) HCMVs affects the intermediary metabolism in 
infected cells –similarly to tumor cells in general, HCMV promotes incomplete 
glucose degradation in the tricarboxylic acid (TCA) cycle for energy: glucose is 
metabolized to citrate, leaves the mitochondria and is used for fatty acid synthesis 
– which in turn promotes glutaminolysis to maintain ATP production 210.
Also, although not directly a part of the hallmarks of cancer, epigenetics is an 
emerging field describing regulations of gene expression, without any changes to 
the underlying DNA sequence. As such, for instance DNA methylation and histone 
modifications are included among these mechanisms of action 211, i.e. with frequent 
hyper- and hypomethylations often present among tumor suppressor genes and 
genome wide hypomethylations in many cancer types affecting gene expression 
212. There is accumulating evidence that viral control of epigenetic mechanisms 
is important for maintenance and life-cycle control of viruses. This was recently 
supported by our own group´s findings, with HCMV shown to re-localize DNMT1 
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and DNMT3a from the nucleus to the cytoplasm to interfere with DNA methylation 
resulting in hypomethylation in MB and in HUVECs 213,214. Further, inhibition of 
HCMV by ganciclovir prevented the cytoplasmic localization of DNMT-1, while 
treatment of HCMV- infected MB cells as well as HUVECs with the methylation 
inhibitor 5-Azacytidine (5AZA), significantly increased HCMV-IE and HCMV-gB 
gene transcription and protein expression. Increased viral protein synthesis in 
5AZA-treated cells suggests that HCMV replication may benefit from a DNA 
methyltransferase-free cellular environment with a hypomethylated DNA and high 
gene transcription. Our results indicate that epigenetic mechanisms are important 
for viral interplay with the cellular genome of the infected cells, and that epigenetic 
mechanisms can impair protective mechanisms of the infected cell while allow-
ing the virus to replicate its genome. Further, these findings also emphasize the 
importance of assessing potential viral activation in the treatment of MB patients 
with epigenetic drugs.
1.5.1 HCMV and DDR
Current knowledge in the field indicates that when HCMV infects cells such host 
cells are forced to adopt a persistent G1/S-phase state, thereby subverting the cell 
cycle machinery to divert the cell’s metabolites and enzymes necessary for viral 
DNA replication 215-217, while suppressing the cells own DNA synthesis 218-221. 
Further, HCMV has been reported to induce DDR to perform tasks for the virus, as 
such, some host DDR proteins have been reported to be localized to viral replica-
tion centers, believed to be aiding in virus genome replication and proof-reading 
in preparation for viral propagation. Nevertheless, the emerging ‘oncomodulatory’ 
role of HCMV in general, and the interplay between HCMV and host DDR poten-
tially contributing to the role of HCMV in tumorigenesis has so far been largely 
uncharted. Nevertheless, the following is now known in the field. 
As discussed earlier, DDR can be activated not only by DNA damage caused by 
exogenic sources such as radiation, but also by intracellular factors, including viral 
infections, the latter as part of the viral strategy to gain benefit by exploiting or 
actively inhibiting different parts of the DDR pathways 107. It has been stated that 
HCMV activates DDR through ATM and downstream signaling during infection, 
which is accompanied by recruitment of ATM and other repair proteins to sites 
of viral DNA replication 108-111. Further, HCMV also alters the cell cycle while 
inducing DDR, with infected permissive cells being driven into the G1/S state that 
assures necessary enzymes and metabolites for viral DNA replication 215-217, while 
at the same time suppressing competitive cellular DNA synthesis of the host 218-221. 
In general, DDR activation mediated by HCMV includes the activation of ATM, 
ATR, CHK1 and CHK2 kinases, with the ensuing phosphorylations of e.g. histone 
H2AX and p53. This DDR activation reflects, at least in part, phosphorylation or 
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binding of the host RB family proteins through 4 known HCMV proteins; IE1, 
IE2, pp71 and pUL97. (Figure 8). These events may, at least in nonpermissive 
cells that do not stop cycling upon infection, release the E2F proteins, lead to 
unscheduled replication events, and thereby cause replication stress with fork 
stalling and colapse, leading to DNA breakage. The resultant ATM activation and 
its downstream phosphorylation targets, including H2AX and p53, contribute to 
checkpoint-mediated modulation of the cell cycle, in permissive cells causing a 
prolonged delay at the G1/S border, with limited DNA replication 108. In addition, 
HCMV pUL35 can activate DDR, causing gamma H2AX and 53BP1 foci for-
mation and induction of cell cycle arrest, further supporting viral replication 222. 
More specifically, the permanent G1/S cell cycle arrest due to HCMV in permissive 
cells is mainly channeled through p53 – the activation of which is increased during 
HCMV infection - functioning as a transcriptional activator aimed at activating 
several downstream genes such as the CDK inhibitor p21, Mdm2 and others 103. 
The activation of the p53 in a normal state leads to cell cycle arrest (when p21 is 
the dominant target gene activated by p53) or to apoptosis (if p53-regulated pro-
apoptotic genes such as Puma or Noxa become activated), but HCMV prohibits 
the p53-Mdm2 interaction, leading to p53 stabilization and the above mentioned 
G1/S phase delay/arrest through p21 activation 103. Generally, one can say that 
the complex interaction between HCMV and the HCMV-permissive cell results 
in the cell being in a state of arrest, albeit still with active mechanisms that favor 
HCMV replication over the host cell’s own DNA synthesis. 
Figure. 8. DDR and HCMV interplay, from 103. 
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1.5.2 HCMV as treatment target in brain tumor patients? 
Since the discovery of HCMV infection in GBM and other brain tumors, and its 
association to poor survival of GBM patients as shown by our group 162, there have 
been, and are currently ongoing, numerous clinical treatment efforts to exploit this 
potential target 223. The rationale for clinical trials is supported by animal data from 
several groups, among other our own data demonstrating HCMV potentiated growth 
of neuroblastoma and medulloblastoma in immunocompromised mice, the growth 
of which was correspondingly decreased when treated with valganciclovir 161,148
Similarly, data from GBM animal models by Heukers et al demonstrates growth 
of glioblastoma cells in an orthotopic intracranial GBM-model in mice increased 
by HCMV US28 and was effectively blocked by US-28 targeting nanobodies – 
resulting in decreased tumor growth 224. 
The focus of the clinical trials is currently in the areas of systemic anti-HCMV 
treatment, DC vaccines and adoptive T cell therapy. As such, our group was the 
first to initiate a randomized clinical trial on the use of add-on systemic anti-viral 
treatment in GBM patients 225. The primary end-point of decreased tumor growth at 
6-months follow up was not achieved, nevertheless, exploratory data demonstrated 
overall survival of median 24 months in the treatment group (in comparison to 13 
months in the control group with similar standard treatment) 226. Further, this trial 
did not demonstrate any major adverse events associated with the anti-viral treat-
ment for this indication. Due to these promising results, a randomized trial with 
the hopes of demonstrating an overall survival benefit in GBM patients treated 
with anti-viral therapy in a controlled setting was recently initiated (EudraCT: 
2019-001083-3). 
More recently, HCMV has also become a target in immunotherapy trials for GBM 
patients. One group from Duke University has successfully targeted HCMV pp65, 
where patients receiving HCMV pp65-expressing dendritic cells (pp65-DCs) in 
combination with vaccine site pre-conditioning using tetanus-diphtheria toxoid, 
demonstrated significantly improved progression-free survival (PFS) and overall 
survival (OS) compared to controls 227. 
Yet another strategy, that of adoptive T cell transfer, based on the discovery of 
HCMV specific T cells aimed at pp65 recognize and kill autologous GBM cells 228, 
has recently shown promising clinical results in terms of increased survival in 
recurrent GBM patients, and without any significant side-effects 229. 
Overall, there is increasing evidence that HCMV is a promising new target in the 
treatment of Glioblastoma. 
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2 AIMS OF THE THESIS
• To investigate whether, and to what extent is the HCMV capable of inducing 
features of stemness in primary GBM cell lines (1st study)
• To investigate the presence of HCMV proteins, DDR and replication stress 
markers in human medulloblastomas, and to assess the response of normal 
(permissive) human cells versus medulloblastoma cells to HCMV infection 
(2nd study) 
• To investigate the DDR and HCMV in the context of human medulloblastoma 
stem cells, and to asses responses to experimental genotoxic treatments. (3rd 
study)
• To investigate the mechanisms through which HCMV (or IE72) subverts 
the host-cell DDR fueling genomic instability and hence likely promoting 
tumorigenesis (4th study) 
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3 RESULTS AND DISCUSSION
In recent years, there has been an ongoing debate in the literature on the potential 
presence and role of HCMV in brain tumors, i.e. GBM and MB. The initial obser-
vation of HCMV presence in GBM tissue was made by Cobbs et al. in 2002 159, 
and was confirmed by several other groups including our own, in the years that 
followed. Our research group was the first to demonstrate a high prevalence of 
HCMV also in MBs 161. Importantly, HCMV nucleic acids and proteins were found 
not to be present in the surrounding tissue (only in the tumor tissue), and they were 
found to be present in different primary intracranial tumor types 148,161,230,231 as well 
as secondary tumors (metastases) 160. Nevertheless, some research groups have 
failed to detect HCMV in brain tumor tissue 232,233, possibly due to the use of sub-
optimal detection protocols for HCMV in tumor tissue specimens. The variable 
results have made the question of presence of HCMV in brain cancer a contro-
versial subject 234. As to the potential role of HCMV in MB and GBM, several 
mechanisms supporting the role of HCMV as a pro-oncogenic (oncomodulatory) 
factor have been investigated as discussed previously. Further, there is mounting 
experimental evidence in vivo (animal models) that anti-HCMV therapy reduces 
tumor growth in both MB and GBM 161,235. 
Clinically, besides identification of HCMV in MB and GBM patient samples, 
the quantity of these has proven to be of prognostic significance 162. Our group 
performed a hypothesis generating phase I/II randomized controlled trial on the 
use of Valganciclovir as add-on to standard radio-chemotherapy in GBM patients. 
The study was underpowered, and we found trends but no significant difference in 
tumor growth at 6 months after diagnosis 225. However, in an exploratory analysis 
we observed increased survival in patients treated with Valganciclovir as compared 
to those that received similar standard of care 226. Still, efficacy needs to be proven 
in a controlled setting, which is the aim of a randomized trial recently initiated 
(EudraCT: 2019-001083-3) in Sweden. 
Overall, the literature so far suggests a possible pro-oncogenic (oncomodulatory) 
role of HCMV in GBM and MB, the action thought to be potentially mediated 
through, among other aspects, HCMV-subverted or deregulated DDR. This poten-
tially opens for new treatment possibilities in the future, and demonstrates the 
importance of further research conducted in this area. To investigate this promising 
topic further, we conducted 4 studies which are part of my thesis.
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3.1 1st study: Cytomegalovirus infection induces a stem 
cell phenotype in human primary glioblastoma cells: 
prognostic significance and biological impact.
Background: In the 1st study, we turned our attention towards Glioblastoma. GBM is 
associated with poor prognosis despite aggressive surgical resection, chemotherapy, 
and radiation therapy. Unfortunately, this standard therapy does not target glioma 
cancer stem cells (GCSCs), a subpopulation of GBM cells that is known for their 
ability to self-renew, proliferate and differentiate into heterogenous tumor cells 
41,236. Considering the previously discussed oncomodulatory abilities of HCMV, we 
sought out to investigate the potential role of HCMV in GBM – more specifically 
in the GSC subpopulation of cells. 
Results and discussion: First, we defined our GCS population as those positive for 
CD133, a renowned surface stem cell marker, while HCMV IE was used to denote 
those cells positive for HCMV. We found that 95% or our clinical GBM samples 
(n=21) expressed HCMV-IE (flow-cytometry), while 91% expressed CD133, and 
approximately 80% were double-positive. When analyzed with respect to overall 
survival versus HCMV IE and/or CD133 positivity, these markers were indepen-
dently as well as combined predicative of shorter overall survival in our patient 
cohort (n=21). This suggests that HCMV might induce an increase an CD133 GBM 
phenotype with shorter patient survival, although it can only be speculated upon 
how this is done; by a paracrine manner with HCMV positive cells maintaining 
CD133 GCS. This virus may alter the tumor microenvironment favoring GSC to 
expand, or by direct infection of GSC, HCMV may induce transcription factors 
regulating CD133 expression 237. 
Second, we further searched for an interaction between HCMV and stem cell 
marker expression in GSC, by infecting adherent GBM cell lines with HCMV and 
analyzing the stem cell marker expression. After infection, we saw an upregulation 
of CD133 (surface marker), Nestin (cytoskeletal protein), SOX-2, OCT-4, Notch 
and Nanog (all transcription factors) but not BMI-1 (transcriptional (repressor) 
suppressor) 238. While surface markers are important for recognition, transcription 
factors are mainly important for proliferation and survival 38. Our experiments imply 
that HCMV plays an active role in the regulation of stem cell marker expression. 
Third, we studied the ability of HCMV to induce neurospehere formation in GBM. 
It has been previously reported that GSC form neurospheres when cultured in 
vitro, with tumor growth upon injection in vivo 38. We observed a similar pattern of 
neurosphere formation in our primary GBM cell lines grown under non-adherent 
conditions, with a markedly increased sphere formation when these cells were 
infected with HCMV, suggesting that HCMV seems to induce a more aggressive 
GSC phenotype in GBM. 
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Fourth, we wanted to see if inhibition of the Notch pathway, known for its impor-
tance in neural stem cell formation 239 and previously shown to be upregulated in 
GBM 240, in any way affected sphere formation. To interfere with the Notch pathway, 
we used a gamma secretase inhibitor, which inhibits the final step in the cleavage 
process leading to Notch activation 43. Our experiment resulted in reduced sphere 
formation of GSC in our HCMV infected GBM cell lines, indicating an importance 
of this pathway in HCMV regulated GBM sphere formation. We observed the same 
response pattern (inhibition of sphere formation) when the HCMV polymerase itself 
was blocked by Ganciclovir. 
Finally, previous reports from our group showed that HCMV has an ability to keep 
neural precursor cells (NPCs) in an undifferentiated state and even induce apop-
tosis 241,242. Here, we sought out to investigate this aspect of HCMV and GSC, by 
inducing differentiation of HCMV infected GSC into neuronal or astrocytic differen-
tiation. We then evaluated neuronal (Tuj1) and astrocytic (GFAP) marker expression 
on uninfected and HCMV infected cells. We observed that only a small population 
of HCMV positive cells had differentiated, while uninfected GCS differentiated 
robustly to neuronal cells or astrocytes, respectively. Thus, our observations sug-
gest that HCMV maintains GCS in an undifferentiated state. 
In summary, our findings imply that HCMV infection induces phenotypic plastic-
ity of GBM cells to promote GSC features and may thereby increase the aggres-
siveness of GBM.
3.2 2nd study: Replication stress, DNA damage 
signaling, and cytomegalovirus infection in 
human medulloblastomas
Background: In the 2nd study, we switched our focus to medulloblastoma. We have 
previously reported on the potential role of HCMV in medulloblastomas 161. Our 
research group earlier demonstrated HCMV presence in medulloblastoma speci-
mens and cell lines, and showed that Ganciclovir inhibited tumor growth in vitro, 
and valganciclovir in vivo growth of xenografted human medulloblastoma tumors. 
Also, we have previously investigated DNA damage pathways in different primary 
brain tumors such as gliomas and intra-cranial germ-cell tumors 243,244, suggesting 
that oncogenic events are probable causes behind activated DDR. Nevertheless, 
no reports have so far focused on analyzing activation of DNA damage response 
pathways and potential replication stress in medulloblastomas. And albeit the role 
of HCMV in the context of DNA damage signaling has been previously discussed 
in literature 103, none have looked at the interaction between DNA damage signaling 
and HCMV in medulloblastomas. To investigate this, we have combined immuno-
histochemical analysis of paediatric medulloblastomas with medulloblastoma cell 
culture models including experimental HCMV infection.  
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Results and discussion: First, using eight established immunohistochemical 
markers previously applied to assess the DNA damage signaling in gliomas and 
germ-cell tumors 243,244, we looked at the DNA damage signaling pathways, which 
demonstrated an overall high level of DNA damage signaling (as defined by gam-
maH2AX) in Medulloblastoma in comparison to germ-cell tumors, but not as high 
as in glioblastomas. Notably, both ATM-Chk2 and ATR-Chk1 DNA damage check-
point kinase cascades were active, with the latter, in combination with formation 
of the so-called 53BP1 bodies in G1 cells 245, indicating endogenous replication 
stress. These results indicate an ongoing active endogenous DDR signaling in 
medulloblastomas without any previous genotoxic treatments (i.e. radiation and /
or chemotherapy), confirming that as in gliomas, these tumors show features of 
chronic replication stress that most likely reflects oncogenic events and ensuing 
DDR activation in medulloblastomas. 
Second, p53, a key tumor suppressor in the DDR signaling pathways 246, demon-
strated a somewhat unusual expression, with low detection rate in especially molecu-
lar subtype 3 and 4 medulloblastomas, in cells that otherwise demonstrated a high 
DDR signaling activation. We propose that this could be due to a combination of 
chromosome 17p deletion (where p53 gene resides) 247 and Wip1 phosphatase over-
expression dephosphorylating p53 248, leading to a high proliferation rate despite 
the ongoing checkpoint signaling. 
Third, in literature HCMV immediate early (IE) and Late antigen detection by 
IHC is often debated, with some groups reporting being unable to detect HCMV 
IE and Late proteins in i.e. childhood brain tumors 233, questioning positive find-
ings previously made by others 161. To investigate this, we used three different 
IHC techniques in parallel, with varying results – i.e. the IHC technique usually 
implemented for detection of DDR signaling and used in some papers aiming at 
HCMV protein detection in human tumors (based on citrate buffer pH 6) – proved 
suboptimal for HCMV protein detection, while the protocol employed by our labo-
ratory previously 161, as well as a protocol utilizing tris buffer (pH 9) demonstrated 
clear HCMV protein detection in medulloblastoma clinical specimen, in contrast 
to the lack of staining in normal cerebellum (control). As such, this demonstrates 
that HCMV detection depends on the tissue processing and staining protocol used. 
Fourth, a human medulloblastoma cell line - and a normal diploid fibroblast cell 
line from ATCC were infected with HCMV and analyzed with immunofluores-
cence (pre- and post-infection) with respect to cyclin A (to identify cells in S/G2 
phase) and 53BP1 bodies in cyclin A-negative/G1 cells (marker of replication 
stress, see above). The analysis showed 53BP1 mis-localization to the cytosol in 
HCMV infected fibroblasts permissive for viral production, while HCMV infected 
medulloblastoma cells (which are non-permissive and survive HCMV infection) 
did not remove their 53BP1 from the nucleus. While the reason for this can only be 
speculated upon, two main scenarios can be discussed; 1) In fibroblasts infected by 
38
HCMV, viral factors remove 53BP1from the viral replication centers so that the 
DDR machinery does not negatively impact viral replication, especially through 
error-prone repair mediated by the host cell’s non-homologous end joining (NHEJ) 
pathway of DSBs, an error-prone mechanism that is favored by 53BP1 and 
might therefore compromise the integrity of the nascent HCMV genome;  and 2) 
medullo blastoma cells are non-permissive, hence no viral replication takes place, 
yet such tumor cells infected with HCMV feature a high degree of chromosomal 
instability, in that 53BP1 presence and its subsequent effect in terms of double-
strand break repair could be beneficial for the survival of the infected tumor cells. 
In other words, the major difference is that unlike the permissive fibroblasts, the 
medulloblastoma cells are non-permissive, i.e. they do not support HCMV repli-
cation and this likely underlies the observed difference in localization of 53BP1.
Finally, we observed an overall increase in 53BP1 expression and 53BP1 bodies 
formation in the HCMV infected specimens, unexpectedly even in cells that were 
themselves not expressing HCMV but were adjacent to HCMV-infected cells in the 
same culture. This surprising phenomenon suggests a possible cell non-autonomous 
mechanism impacting the surrounding cells, resulting in enhanced replication stress 
even in the cells not directly expressing the HCMV proteins, and thereby leading 
to more frequent formation of 53BP1 bodies in G1 cells. 
In summary, our results indicate a constitutively active DDR machinery and pres-
ence of HCMV in medulloblastomas, with unorthodox p53 defects allowing for 
high proliferation despite the ongoing checkpoint signaling. HCMV-associated 
alteration of 53BP1 is indicative of an HCMV-triggered replication stress. These 
events in combination likely contribute to genomic instability and thereby also to 
selection of tumor cell subclones resistant to genotoxic therapies. 
3.3 3rd study:  Cancer cell stemness, responses to 
experimental genotoxic treatments, cytomegalovirus 
protein expression and DNA replication stress in 
pediatric medulloblastomas
Background: In the 3rd study, we continued working on medulloblastomas. In 
this study, we aimed to examine in more detail, two aspects of medulloblastoma 
biology, namely the possible presence of medulloblastoma stem cells (MBSC), 
thought to be responsible for treatment resistance towards standard-of-care radia-
tion and chemotherapy, and that of replication stress.
To address this issue, we examined the known cancer stem cell markers (CD133, 
CD15) as well as VEGFR2 – suggested to be associated with GSC previously 249 
236 – in combination with HCMV protein expression in human medulloblastoma 
specimens. We complemented our IHC experiments with 3 different medullo-
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blastoma cell lines exposed to radiation and hydroxyurea treatment, analyzing the 
DDR pathways for signaling differences while looking at the phenotypes of the 
individual cell lines in the context of HCMV and stemness properties.
Finally, we examined the replication fork in terms of speed and symmetry between 
these cell lines, to estimate the level of replication stress and analyzed this in the 
context of our previous findings.
Results and discussion: First, our immunohistochemistry analysis on clinical 
material identified expression of VEGFR2, CD133 and more widely CD15 in all 
clinical samples. This demonstrates the presence, although in a varying degree, of 
MBSC in our clinical material. The varying expression and small sample size did 
not allow us to draw any correlations to clinical outcome or molecular subclass. 
As such, larger and more advanced studies using double-fluorescence staining 
methods and cell sorting of fresh surgical tissue samples in combination with 
biological cell experiments will be needed to investigate this further.
Second, we took advantage of ATCC available medulloblastoma cell lines D324, 
DAOY (both showing growth and surface marker profiles indicative of largely 
non-stem cell populations) and D283, a cell line that we showed is robustly positive 
for the CD133 stemness marker and grows in a non-adherent and sphere-forming 
manner – resembling a stemness phenotype under standard cell culture conditions. 
Upon experimental infection by HCMV, the CD133-positive D283 cells showed 
a high positivity of the viral IE72/86 protein (up to 60% of the cell population) 
almost comparable with the high degree of infectivity seen in the permissive con-
trol human BJ fibroblast-like fibroblasts. In contrast, the other two cell lines D324 
and DAOY only expressed low frequency of IE72/86 protein positivity, indicating 
that in contrast to the stem-like D283 cells, the non-stem cell lines support much 
lower expression of HCMV.  Thus, the D283 stem cell phenotype appears to allow 
for a non-permissive infection with abundant viral protein expression while not 
causing cell death despite ongoing proliferation of such HCMV-infected tumor 
cells. This is especially interesting in the context of our previous results on GBM 
and HCMV, with HCMV potentiating a GSC (stemness) phenotype which could 
also be correlated to patient outcome 250.
Third, we moved on to externally induce genotoxic stress in experiments via 
irradiation and drug-induced replication stress; achieved by exposing all three 
cell lines to 3 Gy irradiation and adding hydroxyurea (known to result in drug-
induced replication stress), respectively. When irradiated, all three cell lines 
responded by increasing their activity of Chk1 and Chk2, while only the stem-like 
D283 cells showed unexpectedly low phosphorylation on RPA Ser33 and Kap1, 
overall indicating an aberrantly re-wired signaling under replication stress. When 
exposed to hydroxyurea, the D283 cells responded by exceptionally high degree of 
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RPA Ser4/8 phosphorylation, which in combination with constitutively increased 
 gammaH2AX, suggest a high constitutive degree of endogenous replication stress 
that is further exaggerated upon treatment with hydroxyurea. The notion of abnor-
mally high replication stress was confirmed by using DNA fiber assays, whereby 
replication forks in the D283 cells did not recover properly upon a transient expo-
sure to hydroxyurea (in contrast to responses in the non-stem DAOY medullo-
blastoma cells). These observations suggest that replication stress is constitutively 
enhanced in the D283 cells, resulting in impaired DNA replication and fueling 
genomic instability. This adapted rewiring of the DNA damage signaling would 
allow the MBSC to survive and proliferate, while on the other hand enhancing 
genomic instability, thus broadening variation within such tumor cell population, 
and overall increasing the risk of tumor recurrence due to enhanced resistance to 
radio- and chemotherapy 251,252. 
In summary, this study addresses the connections between MBSC (tumor cell 
stemness), DDR machinery and HCMV by examination of clinical samples corro-
borated by functional experiments with model cell lines, leading to new insights 
into the interplay between the above factors. While demonstrating the presence 
of MBSC in clinical samples and certain cell lines, associated susceptibility to 
HCMV infection as well as the presence of aberrant signaling pathways and 
increased endogenous replication stress – the obtained data also open for new 
research into the role of HCMV in MBSC, with potential implications for better 
understanding tumor development and targetable vulnerabilities of especially the 
medulloblastoma stem cells 161. 
3.4 4th study: HCMV triggers replication stress and 
subverts host-cell’s DNA damage response fueling 
genomic instability
Background: In the 4th study, we turned our attention back to GBM and DDR. It 
is known, that when a virus has entered a host cell(s), a competition arises between 
the host DNA and that of the virus – resulting in DDR activation for viral replica-
tion benefit, which has previously been observed with different viruses, among 
them HCMV 103. A subset of DDR activated proteins have been observed to be 
mis-localized to the viral replication centers (VRCs) in HCMV infected cells – 
believed to be used by the HCMV to proofread it´s genome 108. Nevertheless, 
the mechanism behind the HCMV misuse of DDR is still not well-defined, with 
contradictory evidence in literature; i.e. activation of ATM has been reported by 
some to be essential for HCMV replication 253, while others report this not to be 
the case 254,255. Another possibility is that HCMV uses a “hit-and-run” mechanism 
to exert it´s oncomodulatory effect and promote tumorigenesis. Thus, there is still 
no consensus on the molecular mechanism behind the interplay between HCMV 
and DDR. 
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To investigate this in further depth, we used GBM patient samples before- and 
after they received radio- and chemotherapy as well as several different cell models 
including permissive and non-permissive human cells analyzed for HCMV and 
DDR - with the application of extensive laboratory techniques including IHC, 
immunofluorescence, immunoblotting, FACS, DNA fiber assays and PCR.
Results and discussion: First, we infected permissive (fibroblasts) cells and 
analyzed the aspects of viral replication and DDR. We observed that HCMV 
triggered the cellular DDR response and induced mis localization of error prone 
non-homologous end joining (NHEJ) repair proteins to the cytosol, while attract-
ing the proteins that participate in the error-free homologous recombination (HR) 
repair in the VRC. 
Second, we looked at another dogma mentioned previously – postulating that 
ATM/ATR is necessary for viral production 254. We added inhibitors of ATR, ATM 
and a general PIKK inhibitor in different concentrations to cell cultures of virally 
infected fibroblasts. We observed that in low inhibitor concentrations, the viral titer 
went up while at the same time lowering apoptosis. High inhibitor concentrations 
resulted in diminished viral production while at the same time already decreas-
ing cell viability. These observations suggest that ATR/ATM are not necessary 
for viral production, and that the previous studies suggesting the essential role of 
these kinases were confounded, as the lower virus production in fact reflected the 
compromised fitness of such cells cause by the high doses of ATR/ATM inhibitors. 
Third, we investigated if a direct relationship exists between HCMV and DDR – 
and assessed the functional status of DDR when cells were infected with HCMV. 
By treating cells with i) neocarzinostatin, ii) temozolomide or iii) cisplatin, we 
induced DNA lesions in infected and non-infected fibroblasts. We observed increas-
ing levels of gammaH2AX in all cells, albeit the non-infected cells demonstrated 
a diminishing level of gammaH2AX over time, while the infected did not – in 
other words, the kinetics of repairing the DNA lesions caused by exogenous insults 
such as drugs was clearly delayed in the HCMV-infected cells compared with their 
non-infected counterparts, a finding consistent with an earlier report 256. One pos-
sibility is that the DDR protein mis localization to cytosol and sequestration into 
VCR might have resulted in the observed slower DNA repair of the hosts cell own 
DNA lesions, possibly contributing to genomic instability.
Apart from the results above, the two additional, major and novel findings of this 
study were as follows:
A. We discovered a new mechanism through which HCMV might benefit from 
DDR activation in the host cell. We noticed that the viral IE promoter contains 
transcription-factor binding sites, that resembles promotors of host genes 
activated by stress – i.e. including sites for the transcription factors NF-kB, 
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Sp1, AP1 and CREB. As such, stressful insults including DNA damage could 
activate/enhance IE72/86 viral gene expression. More specifically, we could 
show that experimentally induced replication stress increased IE72/86 expres-
sion – which, through IE72/86 causing more replication stress/DNA damage 
in the host cell, generates a positive feedback loop between host cell stress 
response and HCMV IE production. Based on our findings, we propose that 
the IE promotor has been evolutionally shaped to exploit the host-cell DNA 
damage response. 
B. We provided a detailed and novel insight into how HCMV, or even ectopic IE 
proteins, indeed evoke robust replication stress at the level of replication forks 
(forks stalling and collapse as well as DNA breaks) and destabilize the host cell 
genome, including chromosomal aberrations. While permissive cells died when 
the viral particles lyse the cells, the non-permissive tumor cells survived with 
signs of chromosomal instability that are commonly associated with tumori-
genesis, despite no signs of virus production. Thus, a non-permissive infection 
in GBM would fuel DDR mechanism and further enhance HCMV IE promoter 
activity, which may also promote the oncomodulatory, genome-destabilizing 
effects in the absence of virus production.
Finally, the intriguing finding of the feedback loop between the host DDR response 
and HCMV IE expression led us to assess IE 72/86 protein expression in human 
clinical specimens from GBM patients, from whom we obtained tumor tissue 
before- and after recurrence. Since all patients were treated with radio-chemo-
therapy, comparing these matched samples from the same patient gave us insights 
as to the HCMV and DDR interplay in a clinical setting – demonstrating elevated 
HCMV IE72/86 in tumor recurrence cases, overall consistent with our concept that 
chemo/radio-therapy may induce viral re-activation due to the positive feedback-
loop described above (A). 
Overall, in cell models, we were able to demonstrate that HCMV infection in both 
permissive and non-permissive cells induces replication stress and DNA damage, 
indicating one mechanism of how HCMV may plausibly destabilize the host-cell 
genome and thereby fuel/modulate tumorigenic transformation or tumor progres-
sion, as cancer cells are largely non-permissive for the viral production and hence 
survive the infection and chronically express IE proteins. 
Our findings provide novel findings in the quest for elucidating the molecular 
mechanism behind HCMV and DDR interplay, why providing yet another argument 
supporting the role in future clinical trials of combining standard-of-care geno-
toxic treatments (radio- and chemotherapy) with anti-viral drugs in GBM patients. 
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4 CONCLUSION
Currently, treatment of GBM (the most common primary malignant tumor in adults) 
and Medulloblastoma (the most common primary malignant tumor in children) 
may include some combination of surgery, radiation therapy, and chemotherapy. 
The evolution of most brain tumors is unknown, although varying degree of 
genomic instability and infection by human cytomegalovirus (HCMV) is sus-
pected. Nevertheless, the causes of the chromosomal instability/DDR changes and 
its potential links with HCMV infection and/or resistance to genotoxic therapies 
(i.e. radiation and chemotherapy) remain largely unknown. I build the thesis on the 
recent discoveries of HCMV being present in malignant brain tumors. Although 
it is accepted that activation of host DDR occurs in the context of HCMV infec-
tion, this has so far not been linked to replication stress, and such mechanism, its 
links with cancer cell stemness and its consequences for genomic instability have 
so far not been described in malignant brain tumors, which was the focus of my 
thesis. Briefly, the main findings can be summarized as follows;
• We found HCMV-IE proteins to be co-expressed with CD133 in GBM. Upon 
infection with HCMV in vitro, primary GBM cell lines were induced into 
neuro sphere formation while differentiation into neurons, in combination with 
upregulation of CD133, SOX-2, Notch-1, OCT-4 and Nestin, all of which are 
characteristic of GSC. These results were corroborated by demonstrating that 
GCS stayed in a more undifferentiated state when infected with HCMV. Finally, 
addition of gamma-secretase inhibitor and/or ganciclovir to HCMV infected 
GBM cell lines inhibited sphere formation. In summary, these findings suggest 
that HCMV infection induces a more potent GSC phenotype in GBM. 
• We found pronounced activation of DNA damage signaling pathways and 
HCMV presence in clinical medulloblastomas specimen. Further, we demon-
strated that HCMV infection leads to selective 53BP1 mis localization, believed 
to favor viral survival and replication despite replication stress in human 
fibroblasts and medulloblastomas. In summary, these findings suggest wide 
activation of DDR in human medulloblastomas, with HCMV fueling genomic 
instability.
• We found a wide expression of stem cell markers CD133, CD15 and VEGFR2 
in clinical specimens of medulloblastomas. Complemented by functional experi-
ments, we were able to demonstrate differences between MB cell lines, with 
medulloblastoma cells featuring a stemness phenotype being more susceptible 
to HCMV infection, and high level of endogenous DNA damage. In cell lines 
with a stemness phenotype, we noted a slow replication fork progression – a 
hallmark of chronic replication stress. In summary, these finding contribute 
to the evidence of genomic instability in medulloblastomas, with the cell line 
expressing a stemness phenotype associated to HCMV and slow replication 
speed, a surrogate marker correlated with genome destabilization. 
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• We found that cellular stress response genes and viral IE gene promotor shares 
the same transcription factor bindings sites, which enables an enhanced IE72/86 
expression when DDR is upregulated. These results supported a model that 
HCMV infection fuels replication stress and genomic instability, overall consistent 
with the concept of HCMV’s oncomodulatory effects. This notion was further 
substantiated by our findings with clinical GBM specimen, where HCMV 
expression was elevated after previous genotoxic therapies (in recurrent GBM 
tumors). In summary, these findings provide insights into the mechanisms by 
which HCMV evokes a replication stress response, subverting the cellular DDR 
resulting in genomic instability and thereby likely promoting therapy resistance 
and tumor progression.
In terms of clinical trial design, the results of my thesis further support the rationale 
for the already ongoing clinical trial with valganciclovir in human recurrent glio-
blastoma (EudraCT: 2019-001083-3), a scenario which we now know from one of 
my studies is associated with an enhanced load of HCMV IE72/86 proteins, pos-
sibly contributed by the feedback loop from the genotoxic treatment to the HCMV 
IE gene promoter stimulation via host cell transcription factors responding to DNA 
damage and other stresses. 
Another relevant and already ongoing clinical trial called DIRECT (EudraCT: 2016-
000167-16) focuses on recurrent glioblastoma patients in Sweden and Norway. I am 
a contributor to design of this multicenter randomized trial 257. In this trial, standard-
of-care treatment by temozolomide is being compared against a temozolomide and 
add-on combination of disulfiram with copper supplement. Disulfiram is an old 
and safe alcohol aversion drug and a candidate for repurposing in oncology, since 
combined with copper it becomes metabolized in vivo into an anti-cancer compound 
copper-dithiocarb (CuET, for short), which effectively kills diverse types of cancer 
cells including glioblastomas in preclinical trials. CuET also enhances replication 
stress in human tumor cells, and since glioblastomas already feature a high degree 
of replication stress (further enhanced by HCMV, as shown in my thesis), the hope 
is that the disulfiram+copper combination will boost the replication stress in glio-
blastoma cells beyond a tolerable threshold and kill these cancer cells, while spar-
ing normal cells. The first information as to whether this strategy could provide any 
benefit for patients suffering from recurrent glioblastoma will become available to 
the DIRECT trial team during the summer of 2020, based on the interim analyses.
Furthermore, the results from my thesis also support the notion that glioblastomas 
and medulloblastomas might be sensitive to drugs such as inhibitors of ATR or Chk1 
kinases which normally provide a checkpoint response that might help the tumor 
cells to stabilize their replication forks and avoid excessive chromosomal instability 
and cell death under the high degree of chronic replication stress as seen in these 
brain tumors. Inhibitors of ATR, Chk1 and additional checkpoint kinases are being 
evaluated in many pre-clinical settings, and clinical trials may soon follow.
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Besides the clinical trials mentioned above (which also include HCMV vaccines 
being applied in small groups of human glioblastoma patients), there are very impor-
tant issues to be addressed at the basic, mechanistic level to better understand the 
emerging oncogenic/oncomodulatory effects of HCMV infection in humans. Here, 
I just mention two such issues which I regard as very important to be addressed 
in the near future:
First, arguably the most critical, and so-far rather frustrating issue in the field has 
been the inability to reliably detect and then precisely determine the CMV nucleic 
acid sequences present in human brain tumors. While or lab has obtained preliminary 
evidence for an unorthodox variant HCMV sequence from human brain tumors, 
this issue requires a major effort to be conclusively elucidated and confirmed. If 
identified and validated, such HCMV sequences and tools to express them experi-
mentally, would then be explored to directly test the notion of HCMV as a candidate 
oncogenic or oncomodulatory virus, through direct transformation approaches by 
such viral sequences in cell culture and animals. If confirmed to be oncogenic, as 
current data suggest but still do not prove beyond doubt, one could then assess the 
precise mechanisms of such HCMV-mediated transformation or progression of pre-
cancerous cells to full malignancy. In addition, these sequence-defined tools would 
open the long-awaited avenue to also better exploit this knowledge for diagnostic 
and therapeutic purposes in neuro-oncology and beyond.
Second, while our own work including data in this thesis document the fact that 
HCMV causes replication stress, DNA damage and thereby genomic/chromosomal 
instability, much less is known about any potential impact of HCMV on the spec-
trum of point mutations in human cancer in general, and tumors of the brain in 
particular. Here, we and likely other researchers in the field intend to address the 
possibility that HCMV might trigger a robust mutagenic wave by inducing the host 
endogenous APOBEC family enzymes. These are enzymes whose role is primarily 
to attack any invading virus genomes and mutate them into a state that is incapable 
of proper viral propagation and function, thus protecting the host. However, viruses 
such as HIV are known to partly neutralize this APOBEC defense and in fact hijack 
the mutagenic potential for their own benefit, mutating the virus into new variants 
resistant to anti-viral drugs and host immune system. It is not known whether or 
to what extent APOBEC enzymes may be activated by the presence of HCMV in 
human tumors, however the mutation signatures that are attributable to APOBEC 
family’s mutagenic impact are rather common in human tumors in general, and 
therefore it is plausible that HCMV may contribute to this widespread APOBEC-
mediated mutation loads in human cancer.
Overall, the work of my thesis has complemented the current knowledge about 
the potential role of HCMV and DDR/replication stress in Medulloblastoma and 
Glioblastoma, while opening new avenues to explore, giving hope for new and 
improved therapies for future patients.
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